US20120076779A1 - STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph - Google Patents

STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph Download PDF

Info

Publication number
US20120076779A1
US20120076779A1 US13/235,307 US201113235307A US2012076779A1 US 20120076779 A1 US20120076779 A1 US 20120076779A1 US 201113235307 A US201113235307 A US 201113235307A US 2012076779 A1 US2012076779 A1 US 2012076779A1
Authority
US
United States
Prior art keywords
var
composition
specific embodiment
immunoglobulin
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/235,307
Other languages
English (en)
Inventor
Harald Arno Butterweck
Theresa Friederike Bauer
Lucia Hofbauer
Wolfgang Teschner
Oliver Zoechling
Hans-Peter Schwarz
Christa Mayer
Meinhard Hasslacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to US13/235,307 priority Critical patent/US20120076779A1/en
Assigned to BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC. reassignment BAXTER HEALTHCARE S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHWARZ, HANS-PETER, ZOECHLING, OLIVER, HASSLACHER, MEINHARD, MAYER, CHRISTA, BAUER, THERESA FRIEDERIKE, BUTTERWECK, HARALD ARNO, HOFBAUER, LUCIA, TESCHNER, WOLFGANG
Publication of US20120076779A1 publication Critical patent/US20120076779A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • Biologics are medicinal products created by biological processes, including preparations isolated from natural sources (e.g., human plasma) and recombinant DNA technologies. Within the healthcare and pharmaceutical industries, biologics are becoming increasingly important for patient treatment and overall revenue growth (Goodman M. Nat Rev Drug Discov. (2009) November; 8(11):837).
  • One important class of biologic drugs is therapeutic proteins, both isolated from natural sources and recombinantly produced.
  • plasma proteins are manufactured for therapeutic administration by isolation from pooled human plasma (e.g., GAMMAGARD LIQUID® [IVIG, Immune Globulin Intravenous (Human) 10%]; Baxter International, Deerfield, Ill.) and recombinant means (e.g., ADVATE® [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method]; Baxter International, Deerfield, Ill.).
  • GAMMAGARD LIQUID® IVIG, Immune Globulin Intravenous (Human) 10%
  • Baxter International, Deerfield, Ill. recombinant means
  • ADVATE® Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method
  • IV intravenous
  • SQ subcutaneous
  • intramuscular administration although other routes of administration may be used depending upon the therapeutic protein and condition being treated.
  • Most of the immunoglobulins are administered intravenously as larger volumes can be delivered rapidly by the intravenous route to provide the physiologic levels of IgG needed for the effective treatment of various diseases, such as primary immune deficiencies (PID), immune (idiopathic) thrombocytopenic purpura (ITP) and the Kawasaki syndrome. Due to the nature of IV administration, therapy via this route is a slow and timely process, leading to problems with patient compliance.
  • PID primary immune deficiencies
  • ITP immune idiopathic thrombocytopenic purpura
  • Kawasaki syndrome Due to the nature of IV administration, therapy via this route is a slow and timely process, leading to problems with patient compliance.
  • SQ administration of therapeutic proteins is a convenient alternative to intravenous administration. Compared to IV infusions, SQ administration has several advantages. For example, it can reduce the incidence of systemic reactions, it does not require sometimes-difficult IV access, and gives patients more independence.
  • intravenously administrable immunoglobulins have been formulated at acidic pH, effectively increasing their stability in the formulation (products that are formulated at acidic pH are, e.g., Gamunex (Talecris), Gammagard Liquid (Baxter) or Privigen (CSL).
  • products that are formulated at acidic pH are, e.g., Gamunex (Talecris), Gammagard Liquid (Baxter) or Privigen (CSL).
  • compositions e.g., aqueous compositions
  • present invention satisfies these and other needs by, among other aspects, providing immunoglobulin compositions formulated with histidine at mild acidic to neutral pH that stabilize labile therapeutic proteins.
  • the present invention is based in part by the surprising finding that the addition of alkali metal salts to aqueous formulations at mildly acidic to neutral pH stabilizes both plasma-derived and recombinant labile therapeutic proteins.
  • immunoglobulins and coagulation factors formulated at mildly acidic to neutral pH with less than 75 mM of an alkali metal chloride salt are highly unstable.
  • the addition of greater than 75 mM of an alkali metal chloride salt e.g., 100 mM or 150 mM sodium chloride
  • This finding is contrary to the result of adding alkali metal chloride salts to formulations at acidic pH values, which is shown herein to destabilize these compositions.
  • the ability to stably formulate labile proteins allows for the production of therapeutic formulations that are simpler to self-administer.
  • labile therapeutic proteins e.g., immunoglobulins, coagulation factors, etc.
  • the ability to stably formulate labile therapeutic proteins at mildly acidic to neutral pH allows for the manufacture of pharmaceutical compositions that may be administered subcutaneously (SQ) or intramuscularly (IM) without the pain and potential for tissue damage that is associated with the SQ and IM administration of compositions formulated at acidic pH.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.5.
  • the composition comprises from 100 mM to 200 mM of an alkali metal chloride salt.
  • the composition comprises from 125 mM to 175 mM of an alkali metal chloride salt.
  • the composition comprises 150 ⁇ 15 mM an alkali metal chloride salt.
  • the alkali metal chloride salt is sodium chloride.
  • the alkali metal chloride salt is potassium chloride.
  • the amino acid is selected from the group consisting of glycine, proline, and histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the concentration of the amino acid is from 50 mM to 500 mM.
  • the concentration of the amino acid is from 100 mM to 400 mM.
  • the concentration of the amino acid is from 150 mM to 350 mM.
  • the concentration of the amino acid is from 200 mM to 300 mM.
  • the concentration of the amino acid is from 225 mM to 275 mM.
  • the concentration of the amino acid is 250 ⁇ 10 mM.
  • the pH of the composition is from 5.5 to 7.0.
  • the pH of the composition is from 5.5 to 6.5.
  • the pH of the composition is from 5.5 to 6.0.
  • the pH of the composition is from 6.0 to 7.5.
  • the pH of the composition is from 6.0 to 7.0.
  • the pH of the composition is from 6.0 to 6.5.
  • the pH of the composition is from 6.5 to 7.5.
  • the pH of the composition is from 6.5 to 7.0.
  • the pH of the composition is from 7.0 to 7.5.
  • the labile therapeutic protein is a human or humanized protein.
  • the labile therapeutic protein is an immunoglobulin.
  • the immunoglobulin is an IgG immunoglobulin.
  • the immunoglobulin is a polyclonal immunoglobulin.
  • the immunoglobulin is a monoclonal immunoglobulin.
  • the immunoglobulin is a recombinant immunoglobulin.
  • the immunoglobulin is enriched from pooled human plasma.
  • the concentration of the immunoglobulin is 50 ⁇ 5 g/L.
  • the concentration of the immunoglobulin is less than 50 g/L.
  • the concentration of the immunoglobulin is at least 50 g/L.
  • the concentration of the immunoglobulin is from 50 g/L to 150 g/L.
  • the concentration of the immunoglobulin is 100 ⁇ 10 g/L.
  • the concentration of the immunoglobulin is at least 100 g/L.
  • the concentration of the immunoglobulin is 150 ⁇ 15 g/L.
  • the concentration of the immunoglobulin is from 150 g/L to 250 g/L.
  • the concentration of the immunoglobulin is 200 ⁇ 20 g/L.
  • the concentration of the immunoglobulin is at least 200 g/L.
  • compositions provided above at least 95% of the protein in the composition is immunoglobulin.
  • compositions provided above at least 95% of the protein in the composition is IgG immunoglobulin.
  • compositions provided above at least 98% of the protein in the composition is IgG immunoglobulin.
  • the composition is stable for at least 6 months when stored at between about 28° C. and about 32° C.
  • the composition is stable for at least 1 year when stored at between about 28° C. and about 32° C.
  • the composition is stable for at least 2 years when stored at between about 28° C. and about 32° C.
  • the composition is stable for at least 1 month when stored at between about 38° C. and about 42° C.
  • the composition is stable for at least 3 months when stored at between about 38° C. and about 42° C.
  • the composition is stable for at least 6 months when stored at between about 38° C. and about 42° C.
  • the composition is stable for at least 1 year when stored at between about 28° C. and about 32° C.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is between 0% and 5%.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is between 0% and 2%.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is from 0% to 5% and the percentage of immunoglobulin in the monomeric state is from 80% to 100%.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is from 0% to 2% and the percentage of immunoglobulin in the monomeric state is from 85% to 100%.
  • the labile therapeutic protein is a coagulation factor.
  • the coagulation factor is selected from the group consisting of Factor VII, Factor VIII, Factor IX, and von Willebrand Factor (vWF).
  • the coagulation factor is Factor VIII.
  • the pH of the composition is between about 6.0 and about 7.0.
  • the pH of the composition is 6.5 ⁇ 0.2.
  • the composition retains at least 80% of its Factor VIII activity when stored at a temperature between about 2° C. and about 8° C. for at least 1 month.
  • the composition retains at least 80% of its Factor VIII activity when stored at a temperature between about 2° C. and about 8° C. for at least 2 months.
  • the composition retains at least 80% of its Factor VIII activity when stored at a temperature between about 2° C. and about 8° C. for at least 3 months.
  • the coagulation factor is Factor VII.
  • the coagulation factor is Factor IX.
  • the coagulation factor is von Willebrand Factor (vWF).
  • the coagulation factor is a protein K-dependent coagulation complex.
  • the protein K-dependent coagulation complex comprises the coagulation factors Factor II, Factor IX, and Factor X.
  • the protein K-dependent coagulation complex further comprises Factor VII.
  • the labile protein is stable for less than 3 months in an aqueous formulation containing: from 0 mM to 50 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.
  • the labile protein is stable for less than 2 months in an aqueous formulation containing: from 0 mM to 50 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.
  • the labile protein is stable for less than 1 month in an aqueous formulation containing: from 0 mM to 50 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.
  • the labile protein is stable for less than 2 weeks in an aqueous formulation containing: (a) from 0 mM to 50 mM of an alkali metal chloride salt; (b) an amino acid; and (c) a pH of from 5.5 to 7.
  • the composition is formulated for subcutaneous and/or intramuscular administration.
  • the present invention provides a method for stabilizing an aqueous composition of a labile therapeutic protein, the method comprising formulating the composition at a pH between 5.5 and 7.0, wherein the formulated composition comprises: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; and an amino acid.
  • the formulated composition comprises from 100 mM to 200 mM of an alkali metal chloride salt.
  • the formulated composition comprises from 125 mM to 175 mM of an alkali metal chloride salt.
  • the formulated composition comprises 150 ⁇ 15 mM an alkali metal chloride salt.
  • the alkali metal chloride salt is sodium chloride.
  • the alkali metal chloride salt is potassium chloride.
  • the amino acid is selected from the group consisting of glycine, proline, and histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the formulated composition comprises from 50 mM to 500 mM of the amino acid.
  • the formulated composition comprises from 100 mM to 400 mM of the amino acid.
  • the formulated composition comprises from 150 mM to 350 mM of the amino acid.
  • the formulated composition comprises from 200 mM to 300 mM of the amino acid.
  • the formulated composition comprises from 225 mM to 275 mM of the amino acid.
  • the formulated composition comprises from 250 ⁇ 10 mM of the amino acid.
  • the pH of the formulated composition is from 5.5 to 7.0.
  • the pH of the formulated composition is from 5.5 to 6.5.
  • the pH of the formulated composition is from 5.5 to 6.0.
  • the pH of the formulated composition is from 6.0 to 7.5.
  • the pH of the formulated composition is from 6.0 to 7.0.
  • the pH of the formulated composition is from 6.0 to 6.5.
  • the pH of the formulated composition is from 6.5 to 7.5.
  • the pH of the formulated composition is from 6.5 to 7.0.
  • the pH of the formulated composition is from 7.0 to 7.5.
  • the labile therapeutic protein is a human or humanized protein.
  • the labile therapeutic protein is an immunoglobulin.
  • the immunoglobulin is an IgG immunoglobulin.
  • the immunoglobulin is a polyclonal immunoglobulin.
  • the immunoglobulin is a monoclonal immunoglobulin.
  • the immunoglobulin is a recombinant immunoglobulin.
  • the immunoglobulin is enriched from pooled human plasma.
  • the concentration of the immunoglobulin is 50 ⁇ 5 g/L.
  • the concentration of the immunoglobulin is less than 50 g/L.
  • the concentration of the immunoglobulin is at least 50 g/L.
  • the concentration of the immunoglobulin is from 50 g/L to 150 g/L.
  • the concentration of the immunoglobulin is 100 ⁇ 10 g/L.
  • the concentration of the immunoglobulin is at least 100 g/L.
  • the concentration of the immunoglobulin is 150 ⁇ 15 g/L.
  • the concentration of the immunoglobulin is from 150 g/L to 250 g/L.
  • the concentration of the immunoglobulin is 200 ⁇ 20 g/L.
  • the concentration of the immunoglobulin is at least 200 g/L.
  • At least 95% of the protein in the formulated composition is immunoglobulin.
  • At least 95% of the protein in the formulated composition is IgG immunoglobulin.
  • At least 98% of the protein in the formulated composition is IgG immunoglobulin.
  • the formulated composition is stable for at least 6 months when stored at between about 28° C. and about 32° C.
  • the formulated composition is stable for at least 1 year when stored at between about 28° C. and about 32° C.
  • the formulated composition is stable for at least 2 years when stored at between about 28° C. and about 32° C.
  • the formulated composition is stable for at least 1 month when stored at between about 38° C. and about 42° C.
  • the formulate composition is stable for at least 3 months when stored at between about 38° C. and about 42° C.
  • the formulated composition is stable for at least 6 months when stored at between about 38° C. and about 42° C.
  • the formulated composition is stable for at least 1 year when stored at between about 28° C. and about 32° C.
  • the formulated composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is between 0% and 5%.
  • the formulated composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is between 0% and 2%.
  • the formulated composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is from 0% to 5% and the percentage of immunoglobulin in the monomeric state is from 80% to 100%.
  • the formulated composition is considered stable as long as the percentage of immunoglobulin in the aggregated state is from 0% to 2% and the percentage of immunoglobulin in the monomeric state is from 85% to 100%.
  • the labile therapeutic protein is a coagulation factor.
  • the coagulation factor is selected from the group consisting of Factor VII, Factor VIII, Factor IX, and von Willebrand Factor (vWF).
  • the coagulation factor is Factor VIII.
  • the pH of the composition is between about 6.0 and about 7.0.
  • the pH of the composition is 6.5 ⁇ 0.2.
  • the formulated composition retains at least 80% of its Factor VIII activity when stored at a temperature between about 2° C. and about 8° C. for at least 1 month.
  • the formulated composition retains at least 80% of its Factor VIII activity when stored at a temperature between about 2° C. and about 8° C. for at least 2 months.
  • the formulated composition retains at least 80% of its Factor VIII activity when stored at a temperature between about 2° C. and about 8° C. for at least 3 months.
  • the coagulation factor is Factor VII.
  • the coagulation factor is Factor IX.
  • the coagulation factor is von Willebrand Factor (vWF).
  • the coagulation factor is a protein K-dependent coagulation complex.
  • the protein K-dependent coagulation complex comprises the coagulation factors Factor II, Factor IX, and Factor X.
  • the protein K-dependent coagulation complex further comprises Factor VII.
  • the labile protein is stable for less than 3 months in an aqueous formulation containing: from 0 mM to 50 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.
  • the labile protein is stable for less than 2 months in an aqueous formulation containing: from 0 mM to 50 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.
  • the labile protein is stable for less than 1 month in an aqueous formulation containing: from 0 mM to 50 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.
  • the labile protein is stable for less than 2 weeks in an aqueous formulation containing: from 0 mM to 50 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.
  • the composition is formulated for subcutaneous and/or intramuscular administration.
  • FIG. 1 Aggregation of 20% IgG formulations after 6 months storage at 38 to 42° C.
  • FIG. 2 Aggregate formation in Tetabulin NG formulated at neutral pH in the presence of 150 mM sodium chloride during storage at 28 to 32° C.
  • FIG. 3 Aggregate formation in Partobulin NG formulated at neutral pH in the presence of 150 mM sodium chloride during storage at 28 to 32° C.
  • FIG. 4 Differences in Tetanus Anti-toxin potency of Tetabulin NG formulated with 150 mM sodium chloride in a pH range of 5.5 to 7.5 during storage at 28 to 32° C.
  • FIG. 5 Differences in Anti-D potency of Partobulin NG formulated with 150 mM sodium chloride in a pH range of 5.5 to 7.5 during storage at 28° C. to 32° C.
  • FIG. 6 Anti-MIF titer after three months storage at 38° C. to 42° C.
  • FIG. 7 The Factor VIII activity during 12 weeks storage of the aqueous formulation at 2 to 8° C. without sodium chloride.
  • FIG. 8 The Factor VIII activity during 12 weeks storage of the aqueous formulation at 2 to 8° C. with 150 mM sodium chloride.
  • the present invention provides means for stably formulating these labile proteins in aqueous solution at or near neutral pH.
  • the present invention provides labile therapeutic protein compositions stabilized by the addition of moderate levels of alkali metal chloride salts (e.g., 75 mM to 200 mM, preferably 100 mM to 200 mM) to formulations at mildly acidic to neutral pH.
  • alkali metal chloride salts e.g., 75 mM to 200 mM, preferably 100 mM to 200 mM
  • the present invention is based in part on the surprising discovery that labile therapeutic proteins are significantly stabilized at mildly acidic to neutral pH by the addition of an alkali metal chloride salt at a final concentration of between about 75 mM and about 200 mM.
  • Example 3 demonstrates that addition of 150 mM sodium chloride to these plasma-derived immunoglobulin preparations results in reduced protein aggregation at pH values between 5.5 and 6.5 and reduced loss of anti-D titer for Partobulin® NG between pH 5.5 and pH 6.5, while stabilizing the Tetanus anti-toxin titer across the entire range of pH investigated.
  • Example 4 shows that a recombinant anti-MIF antibody formulated at pH 5.6 to 6.5 with 0.25 M glycine and 150 mM sodium chloride was stabilized upon storage at elevated temperatures (38° C. to 42° C.) for six months. Consistent with the previous observations, sodium chloride enhanced degradation when the antibody was formulated at low pH (4.5) and increased aggregation when formulated at a higher pH (pH 7.3).
  • rFVIII recombinant Factor VIII
  • ADVATE® Boxter International; Deerfield Ill.
  • rFVIII is extremely unstable, even at 2° C. to 8° C., in aqueous formulation.
  • ADVATE® is marketed as a lyophilized formulation that is reconstituted immediately prior to administration.
  • Example 5 the inclusion of 150 mM sodium chloride almost completely stabilizes rFVIII activity at pH 6.0 to 7.0, when stored in aqueous formulation at 2° C. to 8° C. for at least 12 weeks. Accordingly, it has now been demonstrated that intermediate levels of an alkali metal chloride salt can stabilize a wide range of labile therapeutic proteins when formulated at a mildly acidic to neutral pH.
  • a “labile therapeutic protein” refers to a class of therapeutically useful proteins that are unstable when formulated at mildly acid to neutral pH in the absence of an alkali metal chloride salt.
  • protein stability can be measured by several different metrics, including aggregation, loss of enzymatic activity, loss of antigenic titer, or degradation.
  • Labile therapeutic proteins will display one or more of these unwanted characteristics when stored at mildly acidic to neutral pH in the absence of an alkali metal chloride salt. The absolute time for which a labile protein is stable will be dependent upon the individual characteristics of the protein, which can be readily determined by the skilled artisan.
  • certain blood coagulations proteins are stable for less than two months under refrigeration when formulated a mildly acidic to neutral pH in the absence of suitable levels of an alkali metal chloride salt.
  • a labile therapeutic protein may be stable at room temperature for less than six months when formulated a mildly acidic to neutral pH in the absence of suitable levels of an alkali metal chloride salt, as compared to more than two years in the presence of moderate levels of an alkali metal chloride salt.
  • a labile protein will show a marked increase in stability upon the addition of an alkali metal chloride salt to a formulation at mildly acid to neutral pH.
  • inclusion of an alkali metal chloride salt may, for example, reduce aggregation of the labile protein by at least about 20%; maintain at least about 20% more enzymatic activity; maintain at least about 20% more antigenic titer; and/or reduce degradation by at least about 20%, when stored for a given period of time.
  • a labile therapeutic protein may be isolated from a natural source (e.g., plasma-derived) or recombinantly produced.
  • labile plasma derived blood proteins such as immunoglobulins, and blood coagulation factors (e.g., Factor VIII) are particularly well suited for formulation as described herein.
  • coagulation proteins include, Factor II (prothrombin), Factor III (platelet tissue factor), Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, von Willebrand Factor (vWF).
  • labile recombinant proteins such as antibodies and blood coagulation factors may be stabilized according to the formulations and methods provided herein.
  • a “storage stable” aqueous composition refers to a protein solution that has been formulated to increase the stability of the protein in solution, for example by at least 20%, over a given storage time.
  • a labile protein solution formulated at a mildly acidic to neutral pH can be made “storage stable” by the addition of a moderate level (about 75 mM to about 200 mM, preferably about 100 mM to about 200 mM) of an alkali metal chloride salt.
  • the stability of the protein in any given formulation can be measured, for example, by monitoring the formation of aggregates, loss of bulk enzymatic activity, loss of antigenic titer or formation of degradation products, over a period of time.
  • the absolute stability of a formulation, and the stabilizing effects of the alkali metal chloride salt will vary dependent upon the labile protein being stabilized.
  • time of stability refers to the length of time a composition is considered stable.
  • the time of stability for a composition may refer to the length of time for which the level of protein aggregation and/or degradation in the composition remains below a certain threshold (e.g., 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.), the length of time a composition maintains an enzymatic activity above a certain threshold (e.g., 100%, 95%, 90, 85, 80, 75, 70, 65, 60, 55, 50, etc.
  • a certain threshold e.g., 100%, 95%, 90, 85, 80, 75, 70, 65, 60, 55, 50, etc.
  • a storage stable aqueous composition of a labile therapeutic protein formulated at mildly acidic to neutral pH with a moderate level of an alkali metal chloride salt will have a longer time of stability than a composition of the same labile therapeutic protein formulated at mildly acidic to neutral pH without a moderate level of an alkali metal chloride salt.
  • a storage stable aqueous composition of a labile therapeutic protein will have a time of stability that is, for example, at least 20% greater than the time of stability for the same composition formulated in the absence of a moderate level of an alkali metal chloride salt, or at least 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190% greater, or at least 2 times greater, or at least 2.5, 3.0 times, 3.5 times, 4.0 times, 4.5 times, 5.0 times, 5.5 times, 6.0 times, 6.5 times, 7.0 times, 7.5 times, 8.0 times, 8.5 times, 9.0 times, 9.5 times, 10 times, or more times greater than the time of stability for the same composition formulated in the absence of a moderate level of an alkali metal chloride salt.
  • the term “stable” refers to a state of a protein composition (e.g., an immunoglobulin solution) suitable for pharmaceutical administration.
  • an immunoglobulin solution is generally considered to be stable when the level of immunoglobulin aggregation and/or degradation in the composition remains below a certain threshold (e.g., below 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.) or the when the antigenic titer remains above a certain threshold (e.g., above 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, etc. of the antigenic titer present in the composition at the start of a storage period).
  • a certain threshold e.g., below 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.
  • the European Pharmacopoeia (Ph. Eur.) standard for normal human immunoglobulins is that the composition has: (i) a monomer and dimer content equal to or greater than 85% of the total area of a standard chromatogram; and (ii) a polymer and aggregate sum content of not more than 10% of the total area of the chromatogram.
  • the sum of the peak areas of the monomer and dimer represents not less than 95 percent and the maximum amount of polymers and aggregates is no more than 2%.
  • a storage-stable immunoglobulin composition provided herein is considered to be stable when at least 85% of the immunoglobulin content is monomeric and no more than 5%, preferably no more than 2%, of the immunoglobulin content is aggregated.
  • “storage” means that a formulation is not immediately administered to a subject once prepared, but is kept for a period of time under particular conditions (e.g. at a particular temperature, under a particular atmosphere, protected from light, etc.) prior to use.
  • a liquid formulation can be kept for days, weeks, months or years, prior to administration to a subject under varied temperatures such as refrigerated (0° to 10° C.) or room temperature (e.g., between about 20° C. and 25° C.).
  • the phrases “no more than X” and “from 0 to X” are equivalent and refer to any concentration between and including 0 and X.
  • the phrases “a concentration of no more than 2%” and “a concentration of from 0% to 2%” are equivalent and include 0%, 1%, and 2%.
  • the phrases “no less than X” refers to any concentration X or higher.
  • the phrase “a concentration of no less than 98%” includes 98%, 99%, and 100%.
  • the phrases “between X and Y” and “from X to X” are equivalent and refer to any concentration between and including X and Y.
  • the phrases “a concentration of between 49% and 51%” and “a concentration of from 49% to 51%” are equivalent and include 49%, 50%, and 51%.
  • an “alkali metal chloride salt” refers to an inorganic salt of an alkali metal and chlorine.
  • the alkali metal chloride salt will be a pharmaceutically acceptable salt, most commonly sodium or potassium chloride.
  • the salt is sodium chloride.
  • an “alkali metal cation” will most commonly refer to a sodium cation (Na + ) or potassium cation (K + ) and can be contributed by an alkali metal chloride salt or other source.
  • a hydrogen ion is not considered an alkali metal cation, and thus the inclusion of hydrochloric acid will not contribute to the alkali metal cation content of the formulation.
  • a “coagulation factor” refers to a protein involved in the intrinsic (contact activation) or extrinsic (tissue factor) pathway of the coagulation cascade.
  • coagulation proteins include, Factor II (prothrombin), Factor III (platelet tissue factor), Factor. V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, von Willebrand Factor (vWF), and the like.
  • Coagulation proteins stabilized by the formulations and methods provided herein may be plasma-derived or recombinantly produced.
  • core coagulation factor refers to any one of Factor VII, Factor VIII, Factor IX, and von Willebrand Factor (vWF), as well as conservative or natural variants, biologically active fragments, and natural isoforms thereof.
  • Factor VIII refers to any form of factor VIII molecule with the typical characteristics of blood coagulation factor VIII, whether derived from blood plasma or produced through the use of recombinant DNA techniques, and including all modified forms of factor VIII.
  • Factor VIII (FVIII) exists naturally and in therapeutic preparations as a heterogeneous distribution of polypeptides arising from a single gene product (see, e.g., Anderson et al., Proc. Natl. Acad. Sci. USA, 83:2979-2983 (1986)).
  • Commercially available examples of therapeutic preparations containing Factor VIII include those sold under the trade names of HEMOFIL M, ADVATE, and RECOMBINATE (available from Baxter Healthcare Corporation, Deerfield, Ill., U.S.A.).
  • an “antibody” refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically bind and recognize an analyte (antigen).
  • the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes.
  • Light chains are classified as either kappa or lambda.
  • Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively.
  • An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD).
  • the N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.
  • the immunoglobulin will consist of an immunoglobulin preparation isolated from pooled plasma (preferably human plasma) comprising IgG immunoglobulins.
  • the term “about” denotes an approximate range of plus or minus 10% from a specified value. For instance, the language “about 20%” encompasses a range of 18-22%. As used herein, about also includes the exact amount. Hence “about 20%” means “about 20%” and also “20%.”
  • terapéuticaally effective amount or dose or “sufficient/effective amount or dose,” it is meant a dose that produces effects for which it is administered.
  • the exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
  • a “stabilizing agent” refers to a chemical, other than an alkali metal chloride salt, which aids in the stabilization of a labile therapeutic agent in an aqueous formulation under mildly acid to neutral pH.
  • suitable stabilizing agents for the formulations and methods provided herein include, without limitation, buffering agents (e.g., TRIS, HEPES, potassium or sodium phosphate, amino acids, etc.), osmolytes (e.g., sugars, sugar alcohols, etc.), bulking agents (e.g., amino acids, etc.), divalent salts, surfactants, and the like.
  • amino acids refers to any natural or non-natural pharmaceutically acceptable amino acid.
  • Non-limiting examples of amino acids include, isoleucine, alanine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, valine, proline, selenocysteine, serine, tyrosine, arginine, histidine, ornithine, taurine, and the like.
  • Any sugar such as mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, dextran, trehalose, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch, and carboxymethylcellulose may be used.
  • a “sugar alcohol” refers to a hydrocarbon having between about 4 and about 8 carbon atoms and at least one hydroxyl group.
  • Non-limiting examples of sugar alcohols that may be used in formulations provided herein include, mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol.
  • the term “activity” refers to a functional activity or activities of a polypeptide or portion thereof associated with a full-length (complete) protein.
  • Functional activities include, but are not limited to, biological activity, catalytic or enzymatic activity, antigenicity (i.e., the ability to bind or compete with a polypeptide for binding to an anti-polypeptide antibody), immunogenicity, ability to form multimers, and the ability to specifically bind to a receptor or ligand for the polypeptide.
  • the present invention provides stabilized formulations of labile proteins for therapeutic administration.
  • the following embodiments are based in part on the unexpected discovery that the addition of moderate levels of an alkali metal chloride salt (i.e., about 75 mM to about 200 mM, preferably about 100 mM to about 200 mM) to formulations at mildly acidic to neutral pH stabilize various plasma-derived and recombinant proteins that are otherwise labile at these pH values.
  • an alkali metal chloride salt i.e., about 75 mM to about 200 mM, preferably about 100 mM to about 200 mM
  • the labile therapeutic protein compositions provided by the present invention take advantage of the increased stability afforded when these proteins are formulated at mildly acidic to neutral pH. Generally, this includes pH values between about 5.5 and about 7.5. In a preferred embodiment, the pH value is between about 5.5 and about 7.0. However, the range of pH values at which any individual labile therapeutic protein is stabilized by the addition of a moderate level (i.e., between about 75 mM and about 200 mM, preferably between about 100 mM and about 200 mM) of an alkali metal chloride salt may vary slightly, dependent upon the properties of the individual protein. For example, in one embodiment, a storage stable formulation will have a pH between about 5.5 and about 7.0.
  • a storage stable formulation will have a pH between about 5.5 and about 6.5. In other embodiments, the pH of the stabilizing formulation will be between about 6.0 and about 7.0. In another embodiment, the pH of the stabilizing formulation will be between about 5.5 and about 6.0. In one embodiment, the pH of the stabilizing formulation will be between about 6.0 and about 6.5. In another embodiment, the pH of the stabilizing formulation will be between about 6.5 and about 7.0. In another embodiment, a storage stable formulation will have a pH between about 6.0 and about 7.5. In another embodiment, a storage stable formulation will have a pH between about 6.5 and about 7.5. In another embodiment, a storage stable formulation will have a pH between about 7.0 and about 7.5.
  • the pH of the stabilizing formulation is 5.5 ⁇ 0.2, 5.6 ⁇ 0.2, 5.7 ⁇ 0.2, 5.8 ⁇ 0.2, 5.9 ⁇ 0.2, 6.0 ⁇ 0.2, 6.1 ⁇ 0.2, 6.2 ⁇ 0.2, 6.3 ⁇ 0.2, 6.4 ⁇ 0.2, 6.5 ⁇ 0.2, 6.6 ⁇ 0.2, 6.7 ⁇ 0.2, 6.8 ⁇ 0.2, 6.9 ⁇ 0.2, 7.0 ⁇ 0.2, 7.1 ⁇ 0.2, 7.2 ⁇ 0.2, 7.3 ⁇ 0.2, 7.4 ⁇ 0.2, or 7.5 ⁇ 0.2.
  • the pH of the stabilizing formulation is 5.5 ⁇ 0.1, 5.6 ⁇ 0.1, 5.7 ⁇ 0.1, 5.8 ⁇ 0.1, 5.9 ⁇ 0.1, 6.0 ⁇ 0.1, 6.1 ⁇ 0.1, 6.2 ⁇ 0.1, 6.3 ⁇ 0.1, 6.4 ⁇ 0.1, 6.5 ⁇ 0.1, 6.6 ⁇ 0.1, 6.7 ⁇ 0.1, 6.8 ⁇ 0.1, 6.9 ⁇ 0.1, 7.0 ⁇ 0.1, 7.1 ⁇ 0.1, 7.2 ⁇ 0.1, 7.3 ⁇ 0.1, 7.4 ⁇ 0.1, or 7.5 ⁇ 0.1.
  • the pH of the stabilizing formulation is 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5.
  • the pharmaceutical compositions provided herein include one or more stabilizing agents.
  • the stabilizing agent is a buffering agent suitable for intravenous, intravitreal, subcutaneous, and/or intramuscular administration.
  • buffering agents suitable for formulating the storage stable compositions provided herein include glycine, histidine, proline, or other amino acids, salts like citrate, phosphate, acetate, glutamate, tartrate, benzoate, lactate, gluconate, malate, succinate, formate, propionate, carbonate, or any combination thereof adjusted to an appropriate pH.
  • the buffering agent will be sufficient to maintain a suitable pH in the formulation for an extended period of time.
  • the present invention provides stabilized formulations of labile therapeutic proteins for therapeutic administration.
  • the following embodiments are based in part on the unexpected discovery that the formulation of labile therapeutic proteins, including but not limited to immunoglobulin and coagulation factors, with a moderate amount of an alkali metal chloride salt at mildly acidic to neutral pH stabilizes proteins that are otherwise labile at these pH values and/or labile when formulated with an alkali metal chloride salt an acidic pH.
  • the formulation of a protein composition at a particular pH may introduce residual counter ions contributed from one or more pH modifying agents.
  • the storage stable compositions provided herein may contain chloride anions contributed from hydrochloric acid, acetate anions contributed from glacial acetic acid, sodium cations contributed from sodium hydroxide, and the like.
  • a storage stable labile therapeutic protein composition consisting of or consisting essentially of: a labile therapeutic protein, a moderate concentration of an alkali metal chloride salt, and a stabilizing agent may further comprise one or more counter ion, as necessitated by the formulation process at the desired pH.
  • a labile therapeutic protein that may benefit from a formulation or method provided herein is stable for less than 3 months at a temperature between 28° C. and 32° C. when in an aqueous formulation containing less than 50 mM of an alkali metal chloride salt at a pH between 5.5 and 7.5, preferably between 5.5 and 7.0.
  • the labile therapeutic protein is stable for less than 2 months at a temperature between 28° C. and 32° C. in an aqueous formulation containing less than 50 mM of an alkali metal chloride salt at a pH between 5.5 and 7.5, preferably between 5.5 and 7.0.
  • the labile therapeutic protein is stable for less than 1 month at a temperature between 28° C.
  • the labile therapeutic protein is stable for less than 2 weeks at a temperature between 28° C. and 32° C. in an aqueous formulation containing less than 50 mM of an alkali metal chloride salt at a pH between 5.5 and 7.5, preferably between 5.5 and 7.0.
  • the labile therapeutic protein is an immunoglobulin.
  • a labile therapeutic protein that may benefit from a formulation or method provided herein is stable for less than 3 months at a temperature between 2° C. and 8° C. when in an aqueous formulation containing less than 50 mM of an alkali metal chloride salt at a pH between 5.5 and 7.5, preferably between 6.0 and 7.5.
  • the labile therapeutic protein is stable for less than 2 months at a temperature between 2° C. and 8° C. in an aqueous formulation containing less than 50 mM of an alkali metal chloride salt at a pH between 5.5 and 7.5, preferably between 6.0 and 7.5.
  • the labile therapeutic protein is stable for less than 1 month at a temperature between 2° C.
  • the labile therapeutic protein is stable for less than 2 weeks at a temperature between 2° C. and 8° C. in an aqueous formulation containing less than 50 mM of an alkali metal chloride salt at a pH between 5.5 and 7.5, preferably between 6.0 and 7.5.
  • the labile therapeutic protein is a coagulation factor.
  • the labile therapeutic protein is Factor VIII.
  • the labile therapeutic protein will be a human protein, a chimeric protein (e.g., a mouse/human chimera or rat/human chimera), or a humanized protein.
  • the labile therapeutic protein will be a recombinant chimeric or humanized monoclonal antibody.
  • the labile therapeutic protein will be a plasma protein, either recombinant or plasma-derived, e.g., a protein composition isolated from pooled human plasma.
  • Non-limiting examples of plasma-derived labile proteins that may be formulated according to the present invention include: Factor II (prothrombin), Factor III (platelet tissue factor), Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, and von Willebrand Factor (vWF).
  • Factor II prothrombin
  • Factor III platelet tissue factor
  • Factor V Factor VII, Factor VIII
  • Factor IX Factor X
  • Factor XI Factor XII
  • Factor XIII Factor von Willebrand Factor
  • the final concentration of the labile therapeutic protein in the formulations provided herein will be dependent upon many factors, including without limitation, the potency and specific activity of the protein, the disease or condition being treated, the route of administration, and other factors that will be well understood by the skilled practitioner.
  • the labile therapeutic protein will be formulated at a low protein concentration, for example, between 0.05 mg/mL and 10 mg/mL, or between 0.1 mg/mL and 20 mg/mL, or between 0.5 mg/mL and 10 mg/mL, or between 0.1 mg/mL and 0.5 mg/mL.
  • the labile therapeutic protein will be formulated at a moderate protein concentration, between 20 mg/mL and 80 mg/mL.
  • the labile therapeutic protein will be formulated at a high protein concentration, between 80 mg/mL and 250 mg/mL.
  • the protein concentration will be between 80 mg/mL and 120 mg/mL.
  • the protein concentration will be between 120 mg/mL and 180 mg/mL.
  • the protein concentration will be between 180 mg/mL and 250 mg/mL.
  • the final protein concentration may be between 0.5% and 25%. In another embodiment, the final protein concentration may be between 0.5% and 20%. In another embodiment, the final protein concentration may be between 0.5% and 15%. In another embodiment, the final protein concentration may be between 0.5% and 10%. In another embodiment, the final protein concentration may be between 0.5% and 5%. In one embodiment, a composition with a final protein concentration as described above will be formulated for intravenous administration.
  • the final protein concentration may be between 5% and 25%. In another embodiment, the final protein concentration may be between 10% and 25%. In another embodiment, the final protein concentration may be between 15% and 25%. In another embodiment, the final protein concentration may be between 20% and 25%. In one embodiment, a composition with a final protein concentration as described above will be formulated for subcutaneous or intramuscular administration.
  • the labile therapeutic protein will be formulated at a final concentration of from 0.05 g/L to 250 g/L. In certain embodiments, the labile protein is formulated at a final concentration of 0.05 ⁇ 0.01 g/L, 0.06 ⁇ 0.01 g/L, 0.07 ⁇ 0.01 g/L, 0.08 ⁇ 0.01 g/L, 0.09 ⁇ 0.01 g/L, 0.1 ⁇ 0.01 g/L, 0.2 ⁇ 0.02 g/L, 0.3 ⁇ 0.03 g/L, 0.4 ⁇ 0.04 g/L, 0.5 ⁇ 0.05 g/L, 0.6 ⁇ 0.06 g/L, 0.7 ⁇ 0.07 g/L, 0.8 ⁇ 0.08 g/L, 0.9 ⁇ 0.09 g/L, 1 ⁇ 0.1 g/L, 210.2 g/L, 3 ⁇ 0.3 g/L, 4 ⁇ 0.4 g/L, 5 ⁇ 0.5 g/L, 6 ⁇ 0.6 g/L, 7 ⁇ 0.7 g/L, 8 ⁇ 0.8 g/L
  • the final concentration of the labile protein in the formulation is 0.05 g/L, 0.06 g/L, 0.07 g/L, 0.08 g/L, 0.09 g/L, 0.1 g/L, 0.2 g/L, 0.3 g/L, 0.4 g/L, 0.5 g/L, 0.6 g/L, 0.7 g/L, 0.8 g/L, 0.9 g/L, 1 g/L, 2 g/L, 3 g/L, 4 g/L, 5 g/L, 6 g/L, 7 g/L, 8 g/L, 9 g/L, 10 g/L, 11 g/L, 12 g/L, 13 g/L, 14 g/L, 15 g/L, 16 g/L, 17 g/L, 18 g/L, 19 g/L, 20 g/L, 21 g/L, 22 g/L, 23 g/L,
  • the formulations provided herein will stabilize a labile therapeutic protein composition when stored at a temperature between 2° C. and 42° C.
  • a labile therapeutic protein will be stabilized by the formulations provided herein when stored under refrigeration, i.e., stored at a temperature between 2° C. and 8° C.
  • a labile therapeutic protein will be stabilized by the formulations provided herein when stored at room temperature, i.e., stored at a temperature between 20° C. and 25° C.
  • the protein may be stabilized when stored at a temperature between 28° C. and 32° C.
  • the protein may be stabilized when stored at a temperature between 38° C. and 42° C.
  • the temperatures at which a labile therapeutic protein will be stabilized by the formulations provided herein will be dependent upon the characteristics of the individual protein, which can readily be determined by one of skill in the art.
  • a storage stable, aqueous composition provided herein will be stable for at least 2 months.
  • the composition will be stable for at least 3 months.
  • the composition will be stable for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or more months.
  • the composition will be stable for at least 6 months.
  • the composition will be stable for at least 1 year.
  • the composition will be stable for at least 2 years.
  • a labile therapeutic protein composition may be stable under storage conditions for at least 25% longer when formulated with an alkali metal chloride salt at a mildly acidic to neutral pH, as provided herein, as compared to the stability of the same protein under mildly acidic to neutral pH in the absence of the alkali metal chloride salt.
  • the composition may be stable for at least 50% longer when formulated according to the present invention, or at least 75%, 100%, 150%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, or longer when formulated according to the present invention.
  • the labile therapeutic protein composition may be stable under storage conditions for from 25% to 1000% longer when formulated with an alkali metal chloride salt at a mildly acidic to neutral pH, as provided herein, as compared to the stability of the same protein under mildly acidic to neutral pH in the absence of the alkali metal chloride salt.
  • the composition may be stable for from 50% to 1000%, 100% to 1000%, 200% to 1000%, 300% to 1000%, 400% to 1000%, 500% to 1000%, 600% to 1000%, or 700% to 1000%, when formulated according to the present invention.
  • Protein stability may be measured using various metrics, including but not limited to, the extent or rate of protein aggregation, the loss of enzymatic activity, the loss of anti-antigen titer, and/or the extent or rate of protein degradation.
  • metrics include but not limited to, the extent or rate of protein aggregation, the loss of enzymatic activity, the loss of anti-antigen titer, and/or the extent or rate of protein degradation.
  • the stability of an enzyme may be determined by monitoring the loss of enzymatic activity over time, but not by monitoring the loss of an anti-antigen titer.
  • the stability of an antibody may be measured by monitoring the loss of anti-antigen titer, but not by enzymatic activity.
  • a labile immunoglobulin composition is an immunoglobulin composition that losses from 20% to 100% of its anti-antigen titer when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months
  • a labile immunoglobulin composition is an immunoglobulin composition that losses from 30% to 100% of its anti-antigen titer when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months
  • a labile immunoglobulin composition is an immunoglobulin composition that losses from 40% to 100% of its anti-antigen titer when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months
  • a labile immunoglobulin composition is an immunoglobulin composition that losses from 50% to 100% of its anti-antigen titer when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 6 months
  • the stability of a labile protein composition may be determined by monitoring the extent or rate of protein aggregation within the formulation.
  • Protein aggregation may be determined for example, by size exclusion chromatography (SEC), high performance size exclusion chromatography (HP-SEC), dynamic light scattering, non-denaturing gel electrophoresis and the like.
  • SEC size exclusion chromatography
  • HP-SEC high performance size exclusion chromatography
  • dynamic light scattering non-denaturing gel electrophoresis and the like.
  • the stability of the composition may be determined by monitoring the loss of bulk enzymatic activity in the preparation. For example, in one embodiment, a 20% loss of enzymatic activity will correspond to an unstable composition. In other embodiments, a 10% loss of enzymatic activity, or a 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or higher loss of enzymatic activity will correspond to an unstable composition.
  • a labile protein composition is an enzyme composition that losses from 10% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.5 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.5 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • a labile protein composition is an enzyme composition that losses from 20% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • a labile protein composition is an enzyme composition that losses from 30% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • a labile protein composition is an enzyme composition that losses from 40% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • a labile protein composition is an enzyme composition that losses from 50% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 1 month.
  • a labile protein composition is an enzyme composition that losses from 10% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.5 and stored at a particular temperature (e.g.; from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.5 and stored at a particular temperature (e.g.; from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • a labile protein composition is an enzyme composition that losses from 20% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • a labile protein composition is an enzyme composition that losses from 30% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • a labile protein composition is an enzyme composition that losses from 40% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • a labile protein composition is an enzyme composition that losses from 50% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 2 months.
  • a labile protein composition is an enzyme composition that losses from 10% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.5 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.5 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • a labile protein composition is an enzyme composition that losses from 20% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • a labile protein composition is an enzyme composition that losses from 30% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • a labile protein composition is an enzyme composition that losses from 40% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • a labile protein composition is an enzyme composition that losses from 50% to 100% of enzymatic activity when formulated with less than 75 mM (i.e., between 0 mM and 75 mM) of an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • 75 mM i.e., between 0 mM and 75 mM
  • an alkali metal chloride salt at a pH from 5.5 to 7.0 and stored at a particular temperature (e.g., from 2° C. to 8° C., from 20° C. to 25° C., from 28° C. to 32° C., or from 38° C. to 42° C.) for between 1 day and 3 months.
  • the stability of a labile protein composition may be determined by monitoring the extent or rate of protein degradation within the formulation.
  • Protein degradation may be determined for example, by size exclusion chromatography (SEC), high performance size exclusion chromatography (HP-SEC), dynamic, light scattering, non-denaturing gel electrophoresis and the like.
  • SEC size exclusion chromatography
  • HP-SEC high performance size exclusion chromatography
  • dynamic, light scattering non-denaturing gel electrophoresis and the like.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein, the composition comprising between 75 mM and 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between 5.5 and 7.5.
  • the stabilizing agent is a buffer.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine, histidine, or proline.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein, the composition consisting essentially of: between 75 mM and 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between 5.5 and 7.5.
  • the stabilizing agent is a buffer.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine, histidine, or proline.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein, the composition consisting of: between 75 mM and 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between 5.5 and 7.5.
  • the stabilizing agent is a buffer.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine, histidine, or proline.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein, the composition comprising: between about 75 mM and about 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between about 5.5 and about 7.5.
  • the stabilizing agent is a buffer.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine, histidine, or proline.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein, the composition consisting essentially of: between about 75 mM and about 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between about 5.5 and about 7.5.
  • the stabilizing agent is a buffer.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine, histidine, or proline.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein, the composition consisting of: between about 75 mM and about 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between about 5.5 and about 7.5.
  • the stabilizing agent is a buffer.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine, histidine, or proline.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • a stabilizing formulation provided herein contains between 75 mM and 200 mM of an alkali metal chloride salt. In a preferred embodiment, the formulation contains between 100 mM and 200 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 150 mM and 200 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 75 mM and 175 mM of an alkali metal chloride salt.
  • the formulation contains between 75 mM and 150 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 75 mM and 125 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 100 mM and 175 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 100 mM and 150 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 100 mM and 125 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 125 mM and 200 mM of an alkali metal chloride salt.
  • the formulation contains between 125 mM and 175 mM of an alkali metal chloride salt. In another embodiment, the formulation contains between 125 mM and 150 mM of an alkali metal chloride salt. In yet other embodiments, the formulation contains 70 ⁇ 7 mM, 75 ⁇ 7.5 mM, 80 ⁇ 8 mM, 90 ⁇ 9 mM, 100 mM ⁇ 10, 110 ⁇ 11 mM, 120 mM ⁇ 12, 125 ⁇ 12.5 mM, 130 ⁇ 13 mM, 140 ⁇ 14 mM, 150 ⁇ 15 mM, 160 ⁇ 16 mM, 170 ⁇ 17 mM, 175 ⁇ 17.5 mM, 180 ⁇ 18 mM, 190 ⁇ 19 mM, 200 ⁇ 20 mM, 210 ⁇ 21 mM, or 220 ⁇ 22 mM of an alkali metal chloride salt.
  • the formulation contains 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105 mM, 110 mM, 115 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 150 mM, 155 mM, 160 mM, 165 mM, 170 mM, 175 mM, 180 mM, 185 mM, 190 mM, 195 mM, 200 mM, 205 mM, 210 mM, 215 mM, or 220 mM of an alkali metal chloride salt.
  • the alkali metal chloride salt is sodium chloride.
  • the alkali metal chloride salt is potassium chloride.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; 150 ⁇ 15 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; 150 ⁇ 15 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; 150 ⁇ 15 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride.
  • Var. 84 Var. 156 Var. 228 Var. 300 Var. 372 Var. 444 Var. 516 5.8 ⁇ 0.2 Var. 13 Var. 85 Var. 157 Var. 229 Var. 301 Var. 373 Var. 445 Var. 517 5.9 ⁇ 0.2 Var. 14 Var. 86 Var. 158 Var. 230 Var. 302 Var. 374 Var. 446 Var.
  • Var. 400 Var. 472 Var. 544 6.5 ⁇ 0.1 Var. 41 Var. 113 Var. 185 Var. 257 Var. 329 Var. 401 Var. 473 Var. 545 6.6 ⁇ 0.1 Var. 42 Var. 114 Var. 186 Var. 258 Var. 330 Var. 402 Var. 474 Var. 546 6.7 ⁇ 0.1 Var. 43 Var. 115 Var. 187 Var. 259 Var. 331 Var. 403 Var. 475 Var. 547 6.8 ⁇ 0.1 Var. 44 Var. 116 Var. 188 Var. 260 Var. 332 Var. 404 Var. 476 Var. 548 6.9 ⁇ 0.1 Var. 45 Var. 117 Var. 189 Var. 261 Var. 333 Var. 405 Var.
  • Var. 554 7.5 ⁇ 0.1 Var. 51 Var. 123 Var. 195 Var. 267 Var. 339 Var. 411 Var. 483 Var. 555 5.5 Var. 52 Var. 124 Var. 196 Var. 268 Var. 340 Var. 412 Var. 484 Var. 556 5.6 Var. 53 Var. 125 Var. 197 Var. 269 Var. 341 Var. 413 Var. 485 Var. 557 5.7 Var. 54 Var. 126 Var. 198 Var. 270 Var. 342 Var. 414 Var. 486 Var. 558 5.8 Var. 55 Var. 127 Var. 199 Var. 271 Var. 343 Var. 415 Var. 487 Var. 559 5.9 Var. 56 Var. 128 Var. 200 Var. 272 Var.
  • Var. 1032 Var. 1104 7.0 ⁇ 0.2 Var. 601 Var. 673 Var. 745 Var. 817 Var. 889 Var. 961 Var. 1033 Var. 1105 7.1 ⁇ 0.2 Var. 602 Var. 674 Var. 746 Var. 818 Var. 890 Var. 962 Var. 1034 Var. 1106 7.2 ⁇ 0.2 Var. 603 Var. 675 Var. 747 Var. 819 Var. 891 Var. 963 Var. 1035 Var. 1107 7.3 ⁇ 0.2 Var. 604 Var. 676 Var. 748 Var. 820 Var. 892 Var. 964 Var. 1036 Var. 1108 7.4 ⁇ 0.2 Var. 605 Var. 677 Var. 749 Var. 821 Var. 893 Var. 965 Var.
  • Var. 1037 Var. 1109 7.5 ⁇ 0.2 Var. 606 Var. 678 Var. 750 Var. 822 Var. 894 Var. 966 Var. 1038 Var. 1110 5.5 ⁇ 0.1 Var. 607 Var. 679 Var. 751 Var. 823 Var. 895 Var. 967 Var. 1039 Var. 1111 5.6 ⁇ 0.1 Var. 608 Var. 680 Var. 752 Var. 824 Var. 896 Var. 968 Var. 1040 Var. 1112 5.7 ⁇ 0.1 Var. 609 Var. 681 Var. 753 Var. 825 Var. 897 Var. 969 Var. 1041 Var. 1113 5.8 ⁇ 0.1 Var. 610 Var. 682 Var. 754 Var. 826 Var. 898 Var. 970 Var.
  • Var. 1042 Var. 1114 5.9 ⁇ 0.1 Var. 611 Var. 683 Var. 755 Var. 827 Var. 899 Var. 971 Var. 1043 Var. 1115 6.0 ⁇ 0.1 Var. 612 Var. 684 Var. 756 Var. 828 Var. 900 Var. 972 Var. 1044 Var. 1116 6.1 ⁇ 0.1 Var. 613 Var. 685 Var. 757 Var. 829 Var. 901 Var. 973 Var. 1045 Var. 1117 6.2 ⁇ 0.1 Var. 614 Var. 686 Var. 758 Var. 830 Var. 902 Var. 974 Var. 1046 Var. 1118 6.3 ⁇ 0.1 Var. 615 Var. 687 Var. 759 Var. 831 Var. 903 Var. 975 Var.
  • Var. 930 Var. 1002 Var. 1074 Var. 1146 7 Var. 643 Var. 715 Var. 787 Var. 859 Var. 931 Var. 1003 Var. 1075 Var. 1147 7.1 Var. 644 Var. 716 Var. 788 Var. 860 Var. 932 Var. 1004 Var. 1076 Var. 1148 7.2 Var. 645 Var. 717 Var. 789 Var. 861 Var. 933 Var. 1005 Var. 1077 Var. 1149 7.3 Var. 646 Var. 718 Var. 790 Var. 862 Var. 934 Var. 1006 Var. 1078 Var. 1150 7.4 Var. 647 Var. 719 Var. 791 Var. 863 Var. 935 Var. 1007 Var. 1079 Var. 1151 7.5 Var. 648 Var. 720 Var. 792 Var. 864 Var. 936 Var. 1008 Var. 1080 Var. 1152
  • Var. 1372 Var. 1444 Var. 1516 Var. 1588 Var. 1660 6.0-7.5 Var. 1157 Var. 1229 Var. 1301 Var. 1373 Var. 1445 Var. 1517 Var. 1589 Var. 1661 6.0-7.0 Var. 1158 Var. 1230 Var. 1302 Var. 1374 Var. 1446 Var. 1518 Var. 1590 Var. 1662 6.0-6.5 Var. 1159 Var. 1231 Var. 1303 Var. 1375 Var. 1447 Var. 1519 Var. 1591 Var. 1663 6.5-7.5 Var. 1160 Var. 1232 Var. 1304 Var. 1376 Var. 1448 Var. 1520 Var. 1592 Var. 1664 6.5-7.0 Var. 1161 Var. 1233 Var. 1305 Var. 1377 Var. 1449 Var.
  • Var. 1603 Var. 1675 6.5 ⁇ 0.2 Var. 1172 Var. 1244 Var. 1316 Var. 1388 Var. 1460 Var. 1532 Var. 1604 Var. 1676 6.6 ⁇ 0.2 Var. 1173 Var. 1245 Var. 1317 Var. 1389 Var. 1461 Var. 1533 Var. 1605 Var. 1677 6.7 ⁇ 0.2 Var. 1174 Var. 1246 Var. 1318 Var. 1390 Var. 1462 Var. 1534 Var. 1606 Var. 1678 6.8 ⁇ 0.2 Var. 1175 Var. 1247 Var. 1319 Var. 1391 Var. 1463 Var. 1535 Var. 1607 Var. 1679 6.9 ⁇ 0.2 Var. 1176 Var. 1248 Var. 1320 Var. 1392 Var. 1464 Var.
  • Var. 1608 Var. 1680 7.0 ⁇ 0.2 Var. 1177 Var. 1249 Var. 1321 Var. 1393 Var. 1465 Var. 1537 Var. 1609 Var. 1681 7.1 ⁇ 0.2 Var. 1178 Var. 1250 Var. 1322 Var. 1394 Var. 1466 Var. 1538 Var. 1610 Var. 1682 7.2 ⁇ 0.2 Var. 1179 Var. 1251 Var. 1323 Var. 1395 Var. 1467 Var. 1539 Var. 1611 Var. 1683 7.3 ⁇ 0.2 Var. 1180 Var. 1252 Var. 1324 Var. 1396 Var. 1468 Var. 1540 Var. 1612 Var. 1684 7.4 ⁇ 0.2 Var. 1181 Var. 1253 Var. 1325 Var. 1397 Var. 1469 Var.
  • Var. 1618 Var. 1690 5.9 ⁇ 0.1 Var. 1187 Var. 1259 Var. 1331 Var. 1403 Var. 1475 Var. 1547 Var. 1619 Var. 1691 6.0 ⁇ 0.1 Var. 1188 Var. 1260 Var. 1332 Var. 1404 Var. 1476 Var. 1548 Var. 1620 Var. 1692 6.1 ⁇ 0.1 Var. 1189 Var. 1261 Var. 1333 Var. 1405 Var. 1477 Var. 1549 Var. 1621 Var. 1693 6.2 ⁇ 0.1 Var. 1190 Var. 1262 Var. 1334 Var. 1406 Var. 1478 Var. 1550 Var. 1622 Var. 1694 6.3 ⁇ 0.1 Var. 1191 Var. 1263 Var. 1335 Var. 1407 Var. 1479 Var.
  • Var. 1633 Var. 1705 7.4 ⁇ 0.1 Var. 1202 Var. 1274 Var. 1346 Var. 1418 Var. 1490 Var. 1562 Var. 1634 Var. 1706 7.5 ⁇ 0.1 Var. 1203 Var. 1275 Var. 1347 Var. 1419 Var. 1491 Var. 1563 Var. 1635 Var. 1707 5.5 Var. 1204 Var. 1276 Var. 1348 Var. 1420 Var. 1492 Var. 1564 Var. 1636 Var. 1708 5.6 Var. 1205 Var. 1277 Var. 1349 Var. 1421 Var. 1493 Var. 1565 Var. 1637 Var. 1709 5.7 Var. 1206 Var. 1278 Var. 1350 Var. 1422 Var. 1494 Var. 1566 Var. 1638 Var. 1710 5.8 Var.
  • Var. 2022 6.0-6.5 Var. 1735 Var. 1807 Var. 1879 Var. 1951 Var. 2023 6.5-7.5 Var. 1736 Var. 1808 Var. 1880 Var. 1952 Var. 2024 6.5-7.0 Var. 1737 Var. 1809 Var. 1881 Var. 1953 Var. 2025 5.5 ⁇ 0.2 Var. 1738 Var. 1810 Var. 1882 Var. 1954 Var. 2026 5.6 ⁇ 0.2 Var. 1739 Var. 1811 Var. 1883 Var. 1955 Var. 2027 5.7 ⁇ 0.2 Var. 1740 Var. 1812 Var. 1884 Var. 1956 Var. 2028 5.8 ⁇ 0.2 Var. 1741 Var. 1813 Var. 1885 Var. 1957 Var. 2029 5.9 ⁇ 0.2 Var. 1742 Var. 1814 Var. 1886 Var.
  • Var. 2030 6.0 ⁇ 0.2 Var. 1743 Var. 1815 Var. 1887 Var. 1959 Var. 2031 6.1 ⁇ 0.2 Var. 1744 Var. 1816 Var. 1888 Var. 1960 Var. 2032 6.2 ⁇ 0.2 Var. 1745 Var. 1817 Var. 1889 Var. 1961 Var. 2033 6.3 ⁇ 0.2 Var. 1746 Var. 1818 Var. 1890 Var. 1962 Var. 2034 6.4 ⁇ 0.2 Var. 1747 Var. 1819 Var. 1891 Var. 1963 Var. 2035 6.5 ⁇ 0.2 Var. 1748 Var. 1820 Var. 1892 Var. 1964 Var. 2036 6.6 ⁇ 0.2 Var. 1749 Var. 1821 Var. 1893 Var. 1965 Var. 2037 6.7 ⁇ 0.2 Var. 1750 Var.
  • Var. 1774 Var. 1846 Var. 1918 Var. 1990 Var. 2062 7.1 ⁇ 0.1 Var. 1775 Var. 1847 Var. 1919 Var. 1991 Var. 2063 7.2 ⁇ 0.1 Var. 1776 Var. 1848 Var. 1920 Var. 1992 Var. 2064 7.3 ⁇ 0.1 Var. 1777 Var. 1849 Var. 1921 Var. 1993 Var. 2065 7.4 ⁇ 0.1 Var. 1778 Var. 1850 Var. 1922 Var. 1994 Var. 2066 7.5 ⁇ 0.1 Var. 1779 Var. 1851 Var. 1923 Var. 1995 Var. 2067 5.5 Var. 1780 Var. 1852 Var. 1924 Var. 1996 Var. 2068 5.6 Var. 1781 Var. 1853 Var.
  • Var. 2078 6.6 Var. 1791 Var. 1863 Var. 1935 Var. 2007 Var. 2079 6.7 Var. 1792 Var. 1864 Var. 1936 Var. 2008 Var. 2080 6.8 Var. 1793 Var. 1865 Var. 1937 Var. 2009 Var. 2081 6.9 Var. 1794 Var. 1866 Var. 1938 Var. 2010 Var. 2082 7 Var. 1795 Var. 1867 Var. 1939 Var. 2011 Var. 2083 7.1 Var. 1796 Var. 1868 Var. 1940 Var. 2012 Var. 2084 7.2 Var. 1797 Var. 1869 Var. 1941 Var. 2013 Var. 2085 7.3 Var. 1798 Var. 1870 Var. 1942 Var. 2014 Var. 2086 7.4 Var. 1799 Var. 1871 Var. 1943 Var. 2015 Var. 2087 7.5 Var. 1800 Var. 1872 Var. 1944 Var. 2016 Var. 2088
  • the pharmaceutical compositions provided herein will typically comprise one or more buffering agents or pH stabilizing agents suitable for intravenous, intravitreal, subcutaneous, and/or intramuscular administration.
  • buffering agents suitable for formulating the storage stable compositions provided herein include glycine, histidine, proline, or other amino acids, salts like citrate, phosphate, acetate, glutamate, tartrate, benzoate, lactate, gluconate, malate, succinate, formate, propionate, carbonate, or any combination thereof adjusted to an appropriate pH.
  • the buffering agent will be sufficient to maintain a suitable pH in the formulation for an extended period of time.
  • the stabilizing agent employed in the storage stable, labile therapeutic protein formulations provided herein is an amino acid.
  • amino acids include, isoleucine, alanine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, valine, proline, selenocysteine, serine, tyrosine, arginine, histidine, ornithine, taurine, combinations thereof, and the like.
  • the stabilizing amino acids include arginine, histidine, lysine, serine, proline, glycine, alanine, threonine, and a combination thereof.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the amino acid will typically be added to the formulation at a concentration between 5 mM and 0.75 M. In one embodiment, at least 100 mM of the amino acid is added to the formulation. In another embodiment, at least 200 mM of the amino acid is added to the formulation. In yet another embodiment, at least 250 mM of the amino acid is added to the formulation.
  • the formulations provided herein will contain at least 25 mM, 50 mM, 75 mM, 100 mM, 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, 500 mM, 550 mM, 600 mM, 650 mM, 700 mM, 750 mM, or more of the amino acid.
  • the concentration of buffering agent in the formulation will be at or about between 5 mM and 500 mM. In certain embodiments, the concentration of the buffering agent in the formulation will be at or about 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 50 mM, 75 mM, 100 mM, 125 mM, 150 mM, 175 mM, 200 mM, 225 mM, 250 mM, 275 mM, 300 mM, 325 mM, 350 mM, 375 mM, 400 mM, 425 mM, 450 mM, 475 mM, 500 mM or higher.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In one embodiment, the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the storage stable labile therapeutic protein aqueous compositions provided herein further comprise one or more excipients.
  • excipients that can be included in the formulations provided herein include non-ionic surfactants, bulking agents (e.g., sugars and sugar alcohols), antioxidants, polysaccharides, and pharmaceutically acceptable water-soluble polymers (e.g., poly(acrylic acid), poly(ethylene oxide), poly(ethylene glycol), poly(vinyl pyrrolidone), hydroxyethyl cellulose, hydroxypropyl cellulose, and starch).
  • the excipient is an agent for adjusting the osmolarity of the composition.
  • osmolarity agents include mannitol, sorbitol, glycerol, sucrose, glucose, dextrose, levulose, fructose, lactose, trehalose, polyethylene glycols, phosphates, calcium chloride, calcium gluconoglucoheptonate, dimethyl sulfone, and the like.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant, and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol, and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0.
  • the pH of the formulation is between 5.5 and 6.5.
  • the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: a labile therapeutic protein; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 5.5 and 7.0. In a specific embodiment, the pH of the formulation is between 5.5 and 6.5. In yet another embodiment, the pH of the formulation is between 6.0 and 7.0.
  • Formulations of the storage stable composition provided herein are delivered to the individual by any pharmaceutically suitable means of administration.
  • Various delivery systems are known and can be used to administer the composition by any convenient route.
  • the compositions of the invention are administered systemically.
  • the composition is formulated for parenteral (e.g. intradermal, subcutaneous, transdermal implant, intracavernous, intravitreal, transscleral, intracerebral, intrathecal, epidural, intravenous, intracardiac, intramuscular, intraosseous, intraperitoneal, and nanocell injection) or enteral (e.g., oral, vaginal or rectal) delivery according to conventional methods.
  • the formulations can be administered continuously by infusion or by bolus injection. Some formulations encompass slow release systems. Preferred routes of administration will depend upon the indication being treated, managed, or prevented.
  • compositions are carried out with the dose levels and pattern being selected by the treating physician.
  • the appropriate dosage depends on the type of disease to be treated, the severity and course of the disease, whether drug is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the therapeutic protein, and the discretion of the attending physician.
  • the storage stable compositions provided herein are formulated for parenteral administration including, but not limited to, intradermal, subcutaneous, transdermal implant, intracavernous, intravitreal, transscleral, intracerebral, intrathecal, epidural, intravenous, intracardiac, intramuscular, intraosseous, intraperitoneal, and nanocell injection administration.
  • the compositions provided herein will be formulated for intravenous administration.
  • the compositions provided herein will be formulated for subcutaneous administration.
  • the compositions provided herein will be formulated for intramuscular administration.
  • the present invention provides storage stable, aqueous immunoglobulin compositions formulated at mildly acidic to neutral pH with a moderate concentration of a metal chloride salt and a stabilizing agent.
  • immunoglobulin may be stabilized by the formulations provided herein.
  • immunoglobulin preparations that may be stabilized include, plasma-derived immunoglobulin preparations, recombinant polyclonal or monoclonal preparations, minibodies, diabodies, triabodies, antibody fragments such as Fv, Fab and F(ab)2 or fragmented antibodies such as monovalent or multivalent single chain Fvs (scFv, sc(Fv)2, minibodies, diabodies, and triabodies such as scFv dimers) in which the variable regions of an antibody are joined together via a linker such as a peptide linker, and the like.
  • a linker such as a peptide linker
  • Recombinant antibodies include murine antibodies, rodent antibodies, human antibodies, chimeric human antibodies (e.g., human/murine chimeras), humanized antibodies (e.g., humanized murine antibodies), and the like.
  • the recombinant antibody is a human, chimeric human, or humanized antibody suitable for administration to a human.
  • the immunoglobulin in a full length, or near full length immunoglobulin, which will generally be more labile then engineered fragments thereof.
  • a storage stable, aqueous immunoglobulin composition will be stable when stored at room temperature for at least about 2 months.
  • the composition will be stable for at least about 3 months.
  • the composition will be stable for at least 1 about month, or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or more months.
  • the composition will be stable for at least about 6 months.
  • the composition will be stable for at least about 1 year.
  • the composition will be stable for at least about 2 years.
  • the storage stable, aqueous immunoglobulin composition will be stable for at least six months at a temperature between about 28° C. and about 32° C. In a specific embodiment, the storage stable, aqueous immunoglobulin composition will be stable for at least one year at a temperature between about 28° C. and about 32° C. In a more specific embodiment, the storage stable, aqueous immunoglobulin composition will be stable for at least two years at a temperature between about 28° C. and about 32° C. In another embodiment, the storage stable, aqueous immunoglobulin composition will be stable for at least one month at a temperature between about 38° C. and about 42° C.
  • the storage stable, aqueous immunoglobulin composition will be stable for at least three months at a temperature between about 38° C. and about 42° C. In a more specific embodiment, the storage stable, aqueous immunoglobulin composition will be stable for at least one year at a temperature between about 38° C. and about 42° C.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 10%. In a preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 9%. In a more preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 8%. In a more preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 7%. In a more preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 6%.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 5%. In a more preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 4%. In a more preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 3%. In a most preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 2%.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 10% and the percentage of immunoglobulin in the monomeric state is no less than 85%. In a preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 9% and the percentage of immunoglobulin in the monomeric state is no less than 85%. In a preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 8% and the percentage of immunoglobulin in the monomeric state is no less than 85%.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 7% and the percentage of immunoglobulin in the monomeric state is no less than 85%. In a preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 6% and the percentage of immunoglobulin in the monomeric state is no less than 85%. In a preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 5% and the percentage of immunoglobulin in the monomeric state is no less than 85%.
  • the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 4% and the percentage of immunoglobulin in the monomeric state is no less than 85%. In a preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 3% and the percentage of immunoglobulin in the monomeric state is no less than 85%. In a most preferred embodiment, the composition is considered stable as long as the percentage of immunoglobulin in the aggregated state no more than 2% and the percentage of immunoglobulin in the monomeric state is no less than 85%.
  • the stability of the composition may be determined by monitoring the loss of anti-antigen titer.
  • the level of anti-antigen titer may be determined, for example, by an immunoassay.
  • immunoassay formats may be used for this purpose.
  • solid-phase ELISA immunoassays are routinely used to determine antigen titer (see, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual (1998) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
  • a 20% loss of anti-antigen titer will correspond to an unstable composition.
  • a 10% loss of anti-antigen titer, or a 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or higher loss of anti-antigen titer will correspond to an unstable composition.
  • aqueous immunoglobulin compositions provided herein are typically sterile filtered and dispensed into a sterile containment vessel, which is sealed air-tight, for example, using a rubber stopper.
  • Immunoglobulin compositions in the air-tight vessels are preferably protected from ambient light by storage in a dark place, the use of a tinted vessel material (typically glass or plastic), and/or covering the surface of the vessel with an opaque substance.
  • the headspace air in the containment vessel is replaced with an inert gas.
  • the inert gas helps to maintain an inert atmosphere above the liquid composition.
  • the liquid is overlaid with inert gas.
  • the liquid is degassed before overlaying it with inert gas, meaning that residual oxygen in the atmosphere may vary.
  • an immunoglobulin composition when stored in a vessel in which the headspace air has been replaced with an inert gas, the composition has been overlaid with inert gas, or the composition is degassed prior to overlaying with inert gas, the composition is said to be “stored under inert gas.”
  • inert gasses include, nitrogen, argon, carbon dioxide, helium, krypton, and xenon.
  • the inert gas is nitrogen.
  • the inert gas is argon.
  • IgG concentrated immunoglobulins isolated from pooled human plasma
  • IVIG intravenous immunoglobulin
  • IgG intravenous immunoglobulin
  • Concentrated immunoglobulins may also be formulated for subcutaneous or intramuscular administration, for example, at a concentration at or about 20% IgG.
  • plasma-derived immunoglobulin preparations formulated according to the present invention can be prepared from any suitable starting materials, for example, recovered plasma or source plasma.
  • blood or plasma is collected from healthy donors.
  • Immunoglobulins are isolated from the blood or plasma by suitable procedures, such as, for example, precipitation (alcohol fractionation or polyethylene glycol fractionation), chromatographic methods (ion exchange chromatography, affinity chromatography, immunoaffinity chromatography, etc.) ultracentrifugation, and electrophoretic preparation, and the like.
  • precipitation alcohol fractionation or polyethylene glycol fractionation
  • chromatographic methods ion exchange chromatography, affinity chromatography, immunoaffinity chromatography, etc.
  • electrophoretic preparation and the like.
  • immunoglobulins are prepared from gamma globulin-containing compositions produced by alcohol fractionation and/or ion exchange and affinity chromatography methods well known to those skilled in the art.
  • purified Cohn Fraction II is commonly used as a starting point for the further purification of immunoglobulins.
  • the starting Cohn Fraction II paste is typically about 95 percent IgG and is comprised of the four IgG subtypes.
  • the different subtypes are present in Fraction II in approximately the same ratio as they are found in the pooled human plasma from which they are obtained.
  • the Fraction II is further purified before formulation into an administrable product.
  • the Fraction II paste can be dissolved in a cold purified aqueous alcohol solution and impurities removed via precipitation and filtration. Following the final filtration, the immunoglobulin suspension can be dialyzed or diafiltered (e.g., using ultrafiltration membranes having a nominal molecular weight limit of less than or equal to 100,000 daltons) to remove the alcohol.
  • the solution can be concentrated or diluted to obtain the desired protein concentration and can be further purified by techniques well known to those skilled in the art.
  • additional preparative steps can be used to enrich a particular isotype or subtype of immunoglobulin.
  • protein A, protein G or protein H sepharose chromatography can be used to enrich a mixture of immunoglobulins for IgG, or for specific IgG subtypes. See generally, Harlow and Lane, Using Antibodies , Cold Spring Harbor Laboratory Press (1999); Harlow and Lane, Antibodies, A Laboratory Manual , Cold Spring Harbor Laboratory Press (1988); and U.S. Pat. No. 5,180,810, the disclosures of which are hereby incorporated by reference in their entireties for all purposes.
  • immunoglobulin compositions isolated from pooled plasma contain impurities carried over from the starting plasma.
  • pharmaceutically acceptable plasma-derived immunoglobulin compositions will contain at least 90% immunoglobulins, preferably at least 95% immunoglobulins, more preferably at least 98% immunoglobulins; most preferably at least 99% immunoglobulins, expressed as a function of total protein content.
  • GAMMAGARD® LIQUID (Baxter International; Deerfield, Ill.) is a plasma-derived immunoglobulin composition formulated at 100 g/L protein.
  • an immunoglobulin composition comprising; consisting essentially of; or consisting of “a plasma-derived immunoglobulin” may contain up to 10% plasma protein impurities carried through during the manufacturing process.
  • the immunoglobulin composition isolated from pooled plasma comprises at least 90% IgG immunoglobulins. In a specific embodiment, the immunoglobulin composition isolated from pooled plasma comprises at least 95% IgG immunoglobulins. In a more specific embodiment, the immunoglobulin composition isolated from pooled plasma comprises at least 98% IgG immunoglobulins. In a yet more specific embodiment, the immunoglobulin composition isolated from pooled plasma comprises at least 99% IgG immunoglobulins. In certain embodiments, the IgG immunoglobulin composition isolated from pooled plasma further comprises IgA and/or IgM immunoglobulins.
  • the immunoglobulin composition isolated from pooled plasma comprises at least 10% IgA. In a specific embodiment, the immunoglobulin composition isolated from pooled plasma comprises at least 25% IgA. In a more specific embodiment, immunoglobulin composition isolated from pooled plasma comprises at least 50% IgA. In yet other embodiments, the immunoglobulin composition isolated from pooled plasma comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more IgA. In certain embodiments, the IgA immunoglobulin composition isolated from pooled plasma further comprises IgG and/or IgM immunoglobulins.
  • the immunoglobulin composition isolated from pooled plasma comprises at least 10% IgM. In a specific embodiment, the immunoglobulin composition isolated from pooled plasma comprises at least 25% IgM. In a more specific embodiment, immunoglobulin composition isolated from pooled plasma comprises at least 50% IgM. In yet other embodiments, the immunoglobulin composition isolated from pooled plasma comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more IgM. In certain embodiments, the IgM immunoglobulin composition isolated from pooled plasma further comprises IgG and/or IgA immunoglobulins.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a plasma-derived immunoglobulin comprising: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a plasma-derived immunoglobulin comprising: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a plasma-derived immunoglobulin; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a plasma-derived immunoglobulin; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the present invention provides a storage stable, aqueous composition consisting of: a plasma-derived immunoglobulin; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the plasma-derived immunoglobulin comprises IgG.
  • the storage stable, plasma derived immunoglobulin composition is a hyper-immune immunoglobulin preparation.
  • the hyper-immune preparation may be an anti-tetanus, anti-D, anti-varicella, anti-rabies, anti-CMV, anti-hepatitis A, or anti-hepatitis B immunoglobulin preparation.
  • plasma derived anti-tetanus and anti-D preparations are stabilized by the addition of between about 100 mM and about 200 mM of an alkali metal chloride salt (e.g., sodium chloride) at a pH between about 5.5 and about 6.5.
  • an alkali metal chloride salt e.g., sodium chloride
  • maximum stability for the hyper-immune immunoglobulin formulations is found between pH 5.5 and 6.0.
  • the present invention provides a storage stable, plasma derived hyper-immune immunoglobulin aqueous composition
  • a storage stable, plasma derived hyper-immune immunoglobulin aqueous composition comprising between about 75 mM and about 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between about 5.5 and about 6.5.
  • the composition comprises between about 100 mM and about 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between about 5.5 and about 6.5.
  • the composition comprises between about 100 mM and about 200 mM of an alkali metal chloride salt, a stabilizing agent, and a pH between about 5.5 and about 6.0.
  • the salt is sodium chloride.
  • the salt is potassium chloride.
  • the storage stable, plasma derived hyper-immune immunoglobulin aqueous compositions provided herein have a protein concentration of between about 30 g/L and about 250 g/L.
  • the protein concentration of the hyper-immune immunoglobulin composition is between about 50 g/L and about 200 g/L, or between about 70 g/L and about 150 g/L, or between about 90 g/L and about 120 g/L, or any suitable concentration within these ranges, for example about 30 g/L, or about 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L, 60 g/L, 65 g/L, 70 g/L, 75 g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, 100 g/L, 105 g/L, 110 g/L, 115 g/L, 120 g/L, 125 g/L,
  • the storage stable plasma derived hyper-immune immunoglobulin aqueous compositions provided herein will be stabilized at room temperature for an extended period of time.
  • the storage stable, aqueous hyper-immune immunoglobulin composition will be stable for at least about 2 months.
  • the composition will be stable for at least about 3 months.
  • the composition will be stable for at least 1 about month, or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or more months.
  • the composition will be stable for at least about 6 months.
  • the composition will be stable for at least about 1 year.
  • the composition will be stable for at least about 2 years.
  • the present invention provides storage stable, recombinant immunoglobulin preparations.
  • Methods for obtaining recombinant antibodies, such as recombinant human antibodies are well known in the art.
  • a desired human antibody having a binding activity for a desired antigen can be obtained by in vitro immunizing human lymphocytes with the desired antigen or a cell expressing the desired antigen and fusing the immunized lymphocytes to human myeloma cells.
  • a desired human antibody can also be obtained by immunizing a transgenic animal having all human antibody gene repertoires with an antigen (see, International Publications Nos.
  • phages binding to an antigen can be selected by expressing the variable regions of a human antibody as single chain antibody fragments (scFv) on phage surfaces by a phage display method.
  • the DNA sequences encoding the variable regions of the human antibody binding to the antigen can be determined by analyzing the genes of the selected phages.
  • a whole human antibody can be obtained by preparing a suitable expression vector containing the determined DNA sequences of the scFv fragments binding to the antigen. These methods have already been well known from WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388.
  • recombinant antibodies can be expressed in tissue or cell culture after transforming a recombinant gene for the construct into a suitable host.
  • Suitable eukaryotic cells for use as hosts include animal, plant and fungal cells.
  • animal cells include (1) mammalian cells such as CHO, COS, myeloma, BHK (baby hamster kidney), HeLa and Vero cells; (2) amphibian cells such as Xenopus oocytes; or (3) insect sells such as sf9, sf21 and Tn5.
  • Known plant cells include cells of Nicotiana such as Nicotiana tabacum , which can be used as callus cultures.
  • fungi include yeasts such as Saccharomyces spp., e.g. Saccharomyces serevisiae and filamentous fungi such as Aspergillus spp., e.g. Aspergillus niger .
  • Prokaryotic cells can be used as producing systems using bacterial cells.
  • Known bacterial cells include E. coli and Bacillus subtilis .
  • Antibodies can be obtained by transforming these cells with an antibody gene of interest and culturing the transformed cells in vitro.
  • the media used to express a recombinant protein can be animal protein-free and chemically defined.
  • Methods of preparing animal protein-free and chemically defined culture mediums are known in the art, for example in US 2008/0009040 and US 2007/0212770, which are both incorporated herein for all purposes.
  • “Protein free” and related terms refers to protein that is from a source exogenous to or other than the cells in the culture, which naturally shed proteins during growth.
  • the culture medium is polypeptide free.
  • the culture medium is serum free.
  • the culture medium is animal protein free.
  • the culture medium is animal component free.
  • the culture medium contains protein, e.g., animal protein from serum such as fetal calf serum.
  • the culture has recombinant proteins exogenously added.
  • the proteins are from a certified pathogen free animal.
  • the term “chemically defined” as used herein shall mean, that the medium does not comprise any undefined supplements, such as, for example, extracts of animal components, organs, glands, plants, or yeast. Accordingly, each component of a chemically defined medium is accurately defined.
  • the media are animal-component free and protein free.
  • a recombinant antibody formulated as provided herein is specific for a polypeptide associated with a disease or disorder.
  • polypeptides include macrophage migration inhibitory factor (MIF), tissue factor pathway inhibitor (TFPI); alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as Factor II (prothrombin), Factor III (platelet tissue factor), Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, and von Willebrand factor; anti-clotting factors such as Antithrombin III (ATIII), Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombes
  • MIF macro
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 5.5 to 7.0.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a recombinant immunoglobulin comprising: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal, chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.0 and 7.0. In a specific embodiment, the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 5.5 to 7.0.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a recombinant immunoglobulin comprising: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody. In a more specific embodiment, the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a recombinant immunoglobulin comprising: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 5.5 to 7.0.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a recombinant immunoglobulin; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a recombinant immunoglobulin; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides a storage stable, aqueous composition consisting of: a recombinant immunoglobulin; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.0 and 7.0.
  • the recombinant immunoglobulin is a monoclonal antibody.
  • the recombinant antibody is an anti-MIF antibody.
  • the present invention provides storage stable, aqueous compositions of labile coagulation factors formulated at mildly acidic to neutral pH with a moderate concentration of a metal chloride salt and a stabilizing agent.
  • alkali metal chloride salts e.g., sodium and potassium chloride
  • the labile coagulation factor is a plasma derived protein or preparation.
  • the labile coagulation protein is a recombinantly expressed coagulation protein.
  • Methods for manufacturing recombinant and plasma derived coagulation factors are well known in the art.
  • Non-limiting examples of labile coagulation factors that may be formulated according to the methods provided herein include, Factor II (prothrombin), Factor III (platelet tissue factor), Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, von Willebrand Factor (vWF), and the like.
  • the labile coagulation protein is selected from Factor VII, Factor VIII, Factor IX, and von Willebrand Factor (vWF).
  • the labile coagulation protein is a vitamin-K dependent protein complex, for example, comprising Factor II, Factor IX, and Factor X, or comprising Factor II, Factor VII, Factor IX, and Factor X.
  • the labile therapeutic coagulation protein is isolated from pooled plasma, i.e., plasma-derived coagulation factors.
  • Methods for the isolation of many different coagulation factors are well known in the art.
  • Furuya et al. (“Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process” Vox Sang. 2006 August; 91(2):119-25) describe a method for the purification of a virally reduced plasma-derived Factor VIII composition from pooled human plasma.
  • the labile therapeutic coagulation protein is expressed recombinantly, i.e., recombinant coagulation factors.
  • Methods for the expression and purification of many different coagulation factors are well known in the art.
  • the media used to express a recombinant coagulation factor can be animal protein-free and chemically defined.
  • Methods of preparing animal protein-free and chemically defined culture mediums are known in the art, for example in US 2008/0009040 and US 2007/0212770, which are both incorporated herein for all purposes.
  • Protein free and related terms refers to protein that is from a source exogenous to or other than the cells in the culture, which naturally shed proteins during growth.
  • the culture medium is polypeptide free.
  • the culture medium is serum free.
  • the culture medium is animal protein free.
  • the culture medium is animal component free.
  • the culture medium contains protein, e.g., animal protein from serum such as fetal calf serum.
  • the culture has recombinant proteins exogenously added.
  • the proteins are from a certified pathogen free animal.
  • the term “chemically defined” as used herein shall mean, that the medium does not comprise any undefined supplements, such as, for example, extracts of animal components, organs, glands, plants, or yeast. Accordingly, each component of a chemically defined medium is accurately defined.
  • the media are animal-component free and protein free.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a coagulation factor; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a coagulation factor; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a coagulation factor; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a′ pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: a coagulation factor; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride. In another embodiment, the metal chloride salt is potassium chloride. In a preferred embodiment, the pH of the formulation is between 6.5 and 7.5. In a specific embodiment, the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition
  • a coagulation factor comprising: a coagulation factor; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: a coagulation factor; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • the present invention provides a storage stable, aqueous composition consisting of: a coagulation factor; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the coagulation factor is a core coagulation factor.
  • recombinant Factor VIII is stabilized by the addition of between about 100 mM and about 200 mM of an alkali metal chloride salt (e.g., sodium chloride) at a pH between about 6.0 and about 7.5.
  • an alkali metal chloride salt e.g., sodium chloride
  • methods are provided for the stabilization of Factor VIII formulated at a pH between 6.0 and 7.5, preferably at a pH from 6.5 to 7.0.
  • the storage stable, aqueous FVIII compositions provided herein have a protein concentration of between 0.05 g/L and 10 g/L.
  • the protein concentration of the FVIII composition is between 0.05 g/L and 2 g/L, or between 0.1 g/L and 1 g/L, or between 0.1 g/L and 0.5 g/L, or any suitable concentration within these ranges, for example 0.05 g/L, or 0.06 g/L, 0.07 g/L, 0.08 g/L, 0.09 g/L, 0.1 g/L, 0.15 g/L, 0.2 g/L, 0.25 g/L, 0.3 g/L, 0.35 g/L, 0.4 g/L, 0.45 g/L, 0.5 g/L, 0.55 g/L, 0.6 g/L, 0.65 g/L, 0.7 g/L, 0.75 g/L, 0.8 g/L, 0.85
  • the aqueous FVIII composition will have a concentration of between 0.1 g/L and 0.5 g/L.
  • the concentration of Factor VIII in a storage-stable aqueous formulation is 0.05 ⁇ 0.01 g/L, or 0.06 ⁇ 0.01 g/L, 0.07 ⁇ 0.01 g/L, 0.08 ⁇ 0.01 g/L, 0.09 ⁇ 0.01 g/L, 0.1 ⁇ 0.01 g/L, 0.15 ⁇ 0.01 g/L, 0.2 ⁇ 0.02 g/L, 0.25 ⁇ 0.02 g/L, 0.3 ⁇ 0.03 g/L, 0.35 ⁇ 0.03 g/L, 0.4 ⁇ 0.04 g/L, 0.45 ⁇ 0.04 g/L, 0.5 ⁇ 0.05 g/L, 0.55 ⁇ 0.05 g/L, 0.6 ⁇ 0.06 g/L, 0.65 ⁇ 0.06 g/L, 0.7 ⁇ 0.07 g/L, 0.75 ⁇ 0.07 g/L, 0.8 ⁇ 0.08
  • the storage stable, aqueous FVIII composition will be stable under refrigeration (i.e., between about 2° C. and about 8° C.) for at least about 1 month. In other embodiments, the storage stable, aqueous FVIII composition will be stable under refrigeration for at least about 2 months. In a preferred embodiment, the storage stable, aqueous FVIII composition will be stable under refrigeration for at least about 3 months. In yet another embodiment, the storage stable, aqueous FVIII composition will be stable under refrigeration for at least about 6 months.
  • the storage stable, aqueous FVIII composition will be stable under refrigeration for at least about 2 weeks, or at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 weeks or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more months under refrigeration.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 125 mM to 175 mM of an alkali metal chloride salt; a stabilizing agent; and a pH of from 6.0 to 7.5.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting essentially of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein consisting of: a labile therapeutic protein; a stabilizing agent; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the stabilizing agent is an amino acid.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; an amino acid; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM glycine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 5 mM to 500 mM glycine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM glycine.
  • the composition contains from 100 mM to 400 mM glycine.
  • the composition contains from 150 mM to 350 mM glycine.
  • the composition contains from 200 mM to 300 mM glycine.
  • the composition contains 250 ⁇ 25 mM glycine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM proline; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 5 mM to 500 mM proline; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM proline.
  • the composition contains from 100 mM to 400 mM proline.
  • the composition contains from 150 mM to 350 mM proline.
  • the composition contains from 200 mM to 300 mM proline.
  • the composition contains 250 ⁇ 25 mM proline.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; from 5 mM to 500 mM histidine; and a pH of from 6.0 to 7.5.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 5 mM to 500 mM histidine; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the composition contains from 25 mM to 500 mM histidine.
  • the composition contains from 100 mM to 400 mM histidine.
  • the composition contains from 150 mM to 350 mM histidine.
  • the composition contains from 200 mM to 300 mM histidine.
  • the composition contains 250 ⁇ 25 mM histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; an antioxidant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; an amino acid; an antioxidant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; a sugar and/or sugar alcohol; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; an amino acid; a sugar and/or sugar alcohol; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains calcium.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; mannitol; trehalose; calcium; a non-ionic surfactant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains an antioxidant.
  • the concentration of mannitol is 38 ⁇ 7 g/L.
  • the concentration of trehalose is 10 ⁇ 2 g/L.
  • the concentration of histidine is 12 ⁇ 2 mM.
  • the concentration of calcium is 1.9 ⁇ 0.4 mM.
  • the non-ionic surfactant is polysorbate-80 at a concentration of 0.15 ⁇ 0.03 g/L.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; mannitol; trehalose; calcium; a non-ionic surfactant; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains an antioxidant.
  • the concentration of mannitol is 38 ⁇ 7 g/L.
  • the concentration of trehalose is 10 ⁇ 2 g/L.
  • the concentration of histidine is 12 ⁇ 2 mM.
  • the concentration of calcium is 1.9 ⁇ 0.4 mM.
  • the non-ionic surfactant is polysorbate-80 at a concentration of 0.15 ⁇ 0.03 g/L.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; from 75 mM to 200 mM of an alkali metal chloride salt; an amino acid; mannitol; trehalose; calcium; a non-ionic surfactant; Tris; glutathione; and a pH of from 6.0 to 7.5.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains an antioxidant.
  • the concentration of mannitol is 38 ⁇ 7 g/L.
  • the concentration of trehalose is 10 ⁇ 2 g/L.
  • the concentration of histidine is 12 ⁇ 2 mM.
  • the concentration of calcium is 1.9 ⁇ 0.4 mM.
  • the non-ionic surfactant is polysorbate-80 at a concentration of 0.15 ⁇ 0.03 g/L.
  • the present invention provides a storage stable, aqueous composition
  • a storage stable, aqueous composition comprising: Factor VIII; an amino acid; mannitol; trehalose; calcium; a non-ionic surfactant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains an antioxidant.
  • the concentration of mannitol is 38 ⁇ 7 g/L.
  • the concentration of trehalose is 10 ⁇ 2 g/L.
  • the concentration of histidine is 12 ⁇ 2 mM.
  • the concentration of calcium is 1.9 ⁇ 0.4 mM.
  • the non-ionic surfactant is polysorbate-80 at a concentration of 0.15 ⁇ 0.03 g/L.
  • the present invention provides a storage stable, aqueous composition consisting essentially of: Factor VIII; an amino acid; mannitol; trehalose; calcium; a non-ionic surfactant; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains an antioxidant.
  • the concentration of mannitol is 38 ⁇ 7 g/L.
  • the concentration of trehalose is 10 ⁇ 2 g/L.
  • the concentration of histidine is 12 ⁇ 2 mM.
  • the concentration of calcium is 1.9 ⁇ 0.4 mM.
  • the non-ionic, surfactant is polysorbate-80 at a concentration of 0.15 ⁇ 0.03 g/L.
  • the present invention provides a storage stable, aqueous composition consisting of: Factor VIII; an amino acid; mannitol; trehalose; calcium; a non-ionic surfactant; Tris; glutathione; and an alkali metal salt/pH combination selected from any one of variations 1 to 2088, as set forth in Table 1, Table 2, Table 3, and Table 4.
  • the amino acid is glycine, proline, or histidine.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid is histidine.
  • the metal chloride salt is sodium chloride.
  • the metal chloride salt is potassium chloride.
  • the pH of the formulation is between 6.5 and 7.5.
  • the composition also contains an antioxidant.
  • the concentration of mannitol is 38 ⁇ 7 g/L.
  • the concentration of trehalose is 10 ⁇ 2 g/L.
  • the concentration of histidine is 12 ⁇ 2 mM.
  • the concentration of calcium is 1.9 ⁇ 0.4 mM.
  • the non-ionic surfactant is polysorbate-80 at a concentration of 0.15 ⁇ 0.03 g/L.
  • a labile therapeutic protein is unstable when formulated at mildly acidic to neutral pH in the absence of an alkaline metal chloride salt.
  • a moderate concentration i.e., between about 75 mM and about 200 mM, preferably between about 100 mM and about 200 mM
  • alkali metal chloride salts provide methods for stabilizing aqueous formulations of labile therapeutic proteins.
  • methods are provided for the stabilization of an aqueous labile therapeutic protein composition. These methods allow for aqueous formulations of labile therapeutic proteins at mildly acidic to neutral pH, which previously required lyophilization, freezing in the presence of several stabilizers, or formulation at extreme pH values.
  • the method comprises the addition of alkali metal chloride salt to a final concentration of between about 75 mM and about 200 mM to an aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 7.5.
  • the method further comprises the addition of a stabilizing agent, such as an amino acid, to the formulation.
  • the method comprises the addition of alkali metal chloride salt to a final concentration of between about 100 mM and about 200 mM to an aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 7.5.
  • the method further comprises the addition of a stabilizing agent, such as an amino acid, to the formulation.
  • the method comprises the addition of alkali metal chloride salt to a final concentration of between about 100 mM and about 200 mM to an aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 7.0.
  • the method further comprises the addition of a stabilizing agent, such as an amino acid, to the formulation.
  • the method comprises the addition of alkali metal chloride salt to a final concentration of between about 75 mM and about 200 mM to an aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 7.0.
  • the method further comprises the addition of a stabilizing agent, such as an amino acid, to the formulation.
  • the methods provided herein for the stabilization of a labile therapeutic protein will further comprise the addition of a stabilizing agent to the formulation.
  • the stabilizing agent will be an amino acid.
  • Exemplary amino acids that may be used for this purpose include, without limitation, arginine, histidine, lysine, serine, proline, glycine, alanine, threonine, and a combination thereof.
  • the amino acid is glycine.
  • the amino acid is proline.
  • the amino acid will typically be added to the formulation at a concentration between about 25 mM and about 0.75 M. In one embodiment, at least about 100 mM of the amino acid is added to the formulation. In another embodiment, at least about 200 mM of the amino acid is added to the formulation. In yet another embodiment, at least about 250 mM of the amino acid is added to the formulation. In yet other embodiments, the formulations provided herein will contain at least about 25 mM of the amino acid, or at least about 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more of the amino acid.
  • the labile therapeutic protein is a human protein, a humanized protein, or a chimeric human protein.
  • the human protein may be either purified from a natural source (e.g., pooled human plasma) or expressed recombinantly, for example in a mammalian cell or tissue culture.
  • the labile therapeutic protein is a plasma-derived protein, preferably a plasma-derived coagulation factor or immunoglobulin preparation.
  • the human, humanized, or chimeric protein in a recombinant antibody or fragment thereof.
  • the methods for stabilizing a formulation of a labile therapeutic protein provided herein comprise the addition of between about 75 mM and about 200 mM of an alkali metal chloride salt to the formulation. In a preferred embodiment, the methods for stabilizing a formulation of a labile therapeutic protein provided herein comprise the addition of between about 100 mM and about 200 mM of an alkali metal chloride salt to the formulation. In certain embodiments, the methods comprise the addition of between about 150 mM and about 200 mM of an alkali metal chloride salt. In other embodiments, the method comprises the addition of between about 150 mM and about 200 mM of an alkali metal chloride salt.
  • the alkali metal chloride salt is sodium chloride.
  • the alkali metal chloride salt is potassium chloride.
  • the methods for stabilizing a labile therapeutic protein comprise formulating the labile protein, in the presence of an alkali metal chloride salt, at a mildly acidic to neutral pH. Generally, this includes pH values between about 5.5 and about 7.5. However, the range of pH values at which any individual labile therapeutic protein is stabilized by the addition of a moderate level (i.e., between about 75 mM and about 200 mM, preferably between about 100 mM and about 200 mM) of an alkali metal chloride salt may vary slightly, dependent upon the properties of the individual protein. In a preferred embodiment, the method will comprise formulating a storage stable composition of a labile therapeutic protein at a pH between about 5.5 and about 7.0.
  • the method will comprise formulating a storage stable composition of a labile therapeutic protein at a pH between about 5.5 and about 6.5.
  • the pH of the stabilizing formulation will be between about 6.0 and about 7.0.
  • the pH of the stabilizing formulation will be between about 5.5 and about 6.0.
  • the pH of the stabilizing formulation will be between about 6.0 and about 6.5.
  • the pH of the stabilizing formulation will be between about 6.5 and about 7.0.
  • the pH of the stabilizing formulation will be between about 6.0 and about 7.5.
  • the pH of the stabilizing formulation will be between about 6.5 and about 7.5.
  • the pH of the stabilizing formulation will be between about 7.0 and about 7.5.
  • the pH of the stabilizing formulation may be at or about 5.5, or at or about 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or at or about 7.5.
  • the method will further comprise formulating the storage stable, labile therapeutic protein for parenteral administration including, but not limited to, intradermal, subcutaneous, transdermal implant, intracavernous, intravitreal, transscleral, intracerebral, intrathecal, epidural, intravenous, intracardiac, intramuscular, intraosseous, intraperitoneal, and nanocell injection administration.
  • the compositions provided herein will be formulated for intravenous administration.
  • the compositions provided herein will be formulated for subcutaneous administration.
  • the compositions provided herein will be formulated for intramuscular administration.
  • the method for stabilizing a labile therapeutic protein will comprise formulating the protein at a final concentration of between about 0.05 mg/mL to about 250 mg/mL.
  • the labile protein will be formulated at a final concentration of about 0.05 mg/mL, 0.06 mg/mL, 0.07 mg/mL, 0.08 mg/mL, 0.09 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL or about 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, 11 mg/mL, 12 mg/mL, 13 mg/mL, 14 mg/mL, 15 mg/mL, 16 mg/mL, 17 mg/mL, 18 mg/mL, 19 mg/mL, 20 mg/m/m
  • the method will comprise formulating the labile therapeutic protein at a low final protein concentration of between about 0.05 mg/mL and about 20 mg/mL.
  • the final protein concentration may be between about 0.5 mg/mL and about 15 mg/mL.
  • the final protein concentration may be between about 0.5 mg/mL and about 10 mg/mL.
  • the final protein concentration may be between about 0.5 mg/mL and about 5 mg/mL.
  • a composition with a final protein concentration as described above will be formulated for intravenous administration.
  • the method will comprise formulating the labile therapeutic protein at a moderate final protein concentration of between about 5 mg/mL and about 25 mg/mL.
  • the final protein concentration may be between about 10 mg/mL and about 25 mg/mL.
  • the final protein concentration may be between about 15 mg/mL and about 25 mg/mL.
  • the final protein concentration may be between about 20 mg/mL and about 25 mg/mL.
  • a composition with a final protein concentration as described above will be formulated for subcutaneous or intramuscular administration.
  • the final protein concentration may be between about 0.5% and about 25%. In another embodiment, the final protein concentration may be between about 0.5% and about 20%. In another embodiment, the final protein concentration may be between about 0.5% and about 15%. In another embodiment, the final protein concentration may be between about 0.5% and about 10%. In another embodiment, the final protein concentration may be between about 0.5% and about 5%. In one embodiment, a composition with a final protein concentration as described above will be formulated for intravenous administration.
  • the final protein concentration may be between about 5% and about 25%. In another embodiment, the final protein concentration may be between about 10% and about 25%. In another embodiment, the final protein concentration may be between about 15% and about 25%. In another embodiment, the final protein concentration may be between about 20% and about 25%. In one embodiment, a composition with a final protein concentration as described above will be formulated for subcutaneous or intramuscular administration.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile plasma derived protein at a pH between about 5.5 and about 7.5, the method comprising adding an alkali metal chloride salt to the formulation at a final concentration of between about 75 mM and about 200 mM.
  • the compositions comprise between about 100 mM and about 200 mM of an alkali metal chloride salt.
  • the mildly acidic to neutral pH is between about 5.5 and about 7.0.
  • the alkali metal chloride salt is sodium chloride.
  • the alkali metal chloride salt is potassium chloride.
  • the storage stable, aqueous labile therapeutic protein composition will be stable for at least about 2 months.
  • the composition will be stable for at least about 3 months.
  • the composition will be stable for at least 1 about month, or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or more months.
  • the composition will be stable for at least about 6 months.
  • the composition will be stable for at least about 1 year.
  • the composition will be stable for at least about 2 years.
  • the formulation will be stabile for an extended period of time at a temperature between about 2° C. and about 42° C.
  • a labile therapeutic protein will be stabilized by the methods provided herein when stored under refrigeration, i.e., stored at a temperature between about 2° C. and about 8° C.
  • a labile therapeutic protein will be stabilized by the methods provided herein when stored at room temperature, i.e., stored at a temperature between about 20° C. and about 25° C.
  • the protein may be stabilized when stored at a temperature between about 28° C. and about 32° C.
  • the protein may be stabilized when stored at a temperature between about 38° C. and about 42° C.
  • the temperatures at which a labile therapeutic protein will be stabilized by the methods provided herein will be dependent upon the characteristics of the individual protein, which can readily be determined by one of skill in the art.
  • the methods provided herein for the stabilization of a labile therapeutic protein comprise the addition of a stabilizing agent.
  • the stabilizing agent comprises one or more buffering agents or pH stabilizing agents suitable for intravenous, intravitreal, subcutaneous, and/or intramuscular administration.
  • buffering agents suitable for formulating the storage stable compositions provided herein include glycine, histidine, or other amino acids, salts like citrate, phosphate, acetate, glutamate, tartrate, benzoate, lactate, gluconate, malate, succinate, formate, propionate, carbonate, or any combination thereof adjusted to an appropriate pH.
  • the buffering agent will be sufficient to maintain a suitable pH in the formulation for an extended period of time.
  • the concentration of buffering agent in the formulation will be at or about between 5 mM and 500 mM. In certain embodiments, the concentration of the buffering agent in the formulation will be at or about 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 50 mM, 75 mM, 100 mM, 125 mM, 150 mM, 175 mM, 200 mM, 225 mM, 250 mM, 275 mM, 300 mM, 325 mM, 350 mM, 375 mM, 400 mM, 425 mM, 450 mM, 475 mM, 500 mM or higher.
  • the stabilizing agent will comprise an agent for adjusting the osmolarity of the composition.
  • osmolarity agents include mannitol, sorbitol, glycerol, sucrose, glucose, dextrose, levulose, fructose, lactose, polyethylene glycols, phosphates, calcium chloride, calcium gluconoglucoheptonate, dimethyl sulfone, and the like.
  • the stabilizing agent employed in the storage stable, labile immunoglobulin formulations provided herein will be an amino acid.
  • Stabilizing amino acids include arginine, histidine, lysine, serine, proline, glycine, alanine, threonine, and a combination thereof.
  • the amino acid is glycine.
  • the amino acid will typically be added to the formulation at a concentration between about 25 mM and about 0.75 M. In one embodiment, at least about 100 mM of the amino acid is added to the formulation. In another embodiment, at least about 200 mM of the amino acid is added to the formulation.
  • At least about 250 mM of the amino acid is added to the formulation.
  • the formulations provided herein will contain at least about 25 mM of the amino acid, or at least about 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or more of the amino acid.
  • the labile plasma derived protein is an immunoglobulin preparation.
  • plasma derived IgG preparations are stabilized by the addition of between about 100 mM and about 200 mM of an alkali metal chloride salt (e.g., sodium chloride) at a pH between about 6.0 and about 7.0.
  • an alkali metal chloride salt e.g., sodium chloride
  • maximum stability for the IgG formulations is found between pH 6.0 and 6.5.
  • the present invention provides method for stabilizing a plasma derived IgG aqueous composition formulated at a pH between about 6.0 and about 7.0, the method comprising adding between about 75 mM and about 200 mM, preferably between about 100 mM and about 200 mM of an alkali metal chloride salt to the formulation.
  • the method further comprises adding a stabilizing agent to the formulation.
  • the method comprises the addition of between about 75 mM and about 200 mM, preferably between about 100 mM and about 200 mM, of an alkali metal chloride salt to a plasma derived immunoglobulin preparation formulated at a pH between about 6.0 and about 6.5.
  • the salt is sodium chloride.
  • the salt is potassium chloride.
  • the method for stabilizing a labile plasma derived immunoglobulin composition will comprise formulating the protein at a final concentration of between about 30 g/L and about 250 g/L.
  • the method comprises formulating the immunoglobulin composition at a final protein concentration of between about 50 g/L and about 200 g/L, or between about 70 g/L and about 150 g/L, or between about 90 g/L and about 120 g/L, or any suitable concentration within these ranges, for example about 30 g/L, or about 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L, 60 g/L, 65 g/L, 70 g/L, 75 g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, 100 g/L, 105 g/L, 110 g/L, 115 g/L, 120 g/L, 125 g/L
  • the aqueous IgG composition will have a concentration of at or about 100 g/L. In a related embodiment, the aqueous IgG composition will have a concentration of between about 70 g/L and about 130 g/L. In another preferred embodiment, the aqueous IgG composition will have a concentration of at or about 200 g/L. In a related embodiment, the aqueous IgG composition will have a concentration of between about 170 g/L and about 230 g/L.
  • the present invention provides methods for stabilizing recombinant immunoglobulin preparations at a pH between about 5.5 and about 7.5 comprising the addition of between about 75 mM and about 200 mM of an alkali metal chloride salt to the formulation.
  • the compositions comprise between about 100 mM and about 200 mM of an alkali metal chloride salt.
  • the mildly acidic to neutral pH is between about 5.5 and about 7.0.
  • the methods further comprise the addition of a stabilizing agent to the formulation.
  • the salt is sodium chloride.
  • the salt is potassium chloride.
  • the storage stable, immunoglobulin composition is a recombinant antibody preparation.
  • a recombinant anti-MIF monoclonal antibody preparation is stabilized by the addition of between about 100 mM and about 200 mM of an alkali metal chloride salt (e.g., sodium chloride) at a pH between about 5.5 and about 6.5.
  • an alkali metal chloride salt e.g., sodium chloride
  • the present invention provides methods for stabilizing aqueous compositions of recombinant immunoglobulins formulated at a pH between about 5.5 and about 6.5 by the addition of between about 75 mM and about 200 mM, preferably between about 100 mM and about 200 mM, of an alkali metal chloride salt and optionally, a stabilizing agent to the formulation.
  • the salt is sodium chloride.
  • the salt is potassium chloride.
  • the methods for stabilizing a recombinant immunoglobulin aqueous composition provided herein comprise the formulation of the recombinant immunoglobulin at a final protein concentration of between about 1 g/L and about 250 g/L.
  • the protein concentration of the recombinant immunoglobulin composition is between about 50 g/L and about 200 g/L, or between about 70 g/L and about 150 g/L, or between about 90 g/L and about 120 g/L, or any suitable concentration within these ranges, for example about 1 g/L, 2 g/L, 3 g/L, 4 g/L, 5 g/L, 6 g/L, 7 g/L, 8 g/L, 9 g/L, 10 g/L, 11 g/L, 12 g/L, 13 g/L, 14 g/L, 15 g/L, 16 g/L, 17 g/L, 18 g/L, 19 g/L, 20 g/L, 25 g/L, 30 g/L, or about 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L, 60 g/L, 65 g/L
  • the present invention provides methods for stabilizing a labile coagulation factor formulated at a pH between about 5.5 and about 7.5 comprising the addition of between about 75 mM and about 200 mM of an alkali metal chloride salt to the formulation.
  • the compositions comprise between about 100 mM and about 200 mM of an alkali metal chloride salt.
  • the mildly acidic to neutral pH is between about 5.5 and about 7.0.
  • the methods further comprise the addition of a stabilizing agent to the formulation.
  • the salt is sodium chloride.
  • the salt is potassium chloride.
  • the labile coagulation protein is a plasma derived protein or preparation. In other embodiments, the labile coagulation protein is a recombinantly expressed coagulation protein. Methods for manufacturing recombinant and plasma derived coagulation factors are well known in the art. Non-limiting examples of coagulation factors that may be formulated according to the methods provided herein include, Factor II (prothrombin), Factor III (platelet tissue factor), Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, von Willebrand Factor (vWF), and the like.
  • Factor II prothrombin
  • Factor III platelet tissue factor
  • Factor V Factor VII, Factor VIII
  • Factor IX Factor X
  • Factor XI Factor XII
  • Factor XIII von Willebrand Factor
  • the labile coagulation protein is selected from Factor VII, Factor VIII, Factor IX, and von Willebrand Factor (vWF).
  • the labile coagulation protein is a vitamin-K dependent protein complex, for example, comprising Factor II, Factor IX, and Factor X, or comprising Factor II, Factor VII, Factor IX, and Factor X.
  • methods are provided for the stabilization of Factor VIII formulated at a pH between about 6.5 and about 7.0.
  • recombinant Factor VIII rFVIII
  • an alkali metal chloride salt e.g., sodium chloride
  • the present invention provides a method for stabilizing an aqueous composition of FVIII, the method comprising formulating a FVIII composition at a pH between about 6.5 and about 7.0 with between about 75 mM and about 200 mM, preferably between about 100 mM and about 200 mM, of an alkali metal chloride salt.
  • the alkali metal chloride salt is sodium chloride.
  • the alkali metal chloride salt is potassium chloride.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 7.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 75 mM and about 200 mM.
  • the compositions comprise between about 100 mM and about 200 mM of an alkali metal chloride salt.
  • the mildly acidic to neutral pH is between about 5.5 and about 7.0.
  • the salt is sodium chloride.
  • the method further comprises the addition of a stabilizing agent.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine or proline.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 6.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 100 mM and about 200 mM.
  • the salt is sodium chloride.
  • the method further comprises the addition of a stabilizing agent.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine or proline.
  • the labile therapeutic protein is a human or humanized protein. In another embodiment of the methods provided herein, the labile therapeutic protein is a recombinant protein. In yet another embodiment of the methods provided herein, the labile therapeutic protein is a plasma-derived protein.
  • the labile therapeutic protein is an immunoglobulin.
  • the immunoglobulin is an IgG preparation.
  • the immunoglobulin is a recombinant antibody.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile immunoglobulin preparation at a pH between about 5.5 and about 7.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 75 mM and about 200 mM, wherein the method stabilizes the immunoglobulin composition for at least 6 months when stored at a temperature at or below about 42° C., for example, at a temperature between about 38° C. and about 42° C.
  • the pH of the immunoglobulin formulation is between about 5.5 and about 6.5.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile immunoglobulin preparation at a pH between about 5.5 and about 7.0, the method comprising addition of an alkali metal chloride salt at a concentration of between about 100 mM and about 200 mM, wherein the method stabilizes the immunoglobulin composition for at least 6 months when stored at a temperature at or below about 42° C., for example, at a temperature between about 38° C. and about 42° C.
  • the pH of the immunoglobulin formulation is between about 5.5 and about 6.5.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile immunoglobulin preparation at a pH between about 5.5 and about 7.0, the method comprising addition of an alkali metal chloride salt at a concentration of between about 100 mM and about 200 mM, wherein the method stabilizes the immunoglobulin composition for at least about one year when stored at a temperature at or below about 32° C., for example, at a temperature between about 28° C. and about 32° C.
  • the pH of the immunoglobulin formulation is between about 5.5 and about 6.5.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile immunoglobulin preparation at a pH between about 5.5 and about 7.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 75 mM and about 200 mM, wherein the method stabilizes the immunoglobulin composition for at least about one year when stored at a temperature at or below about 32° C., for example, at a temperature between about 28° C. and about 32° C.
  • the pH of the immunoglobulin formulation is between about 5.5 and about 6.5.
  • the labile therapeutic protein is a labile coagulation protein.
  • the coagulation protein is Factor VIII.
  • the coagulation protein is Factor VII.
  • the coagulation protein is Factor IX.
  • the coagulation protein is a protein K-dependent coagulation complex, for example, comprising Factor II, Factor IX, and Factor X, or comprising Factor II, Factor VII, Factor IX, and Factor X.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile coagulation protein at a pH between about 5.5 and about 7.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 75 mM and about 200 mM, wherein the method stabilizes the coagulation protein for at least 3 months when stored at a refrigerated temperature, for example, at a temperature between about 2° C. and about 10° C.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile coagulation protein at a pH between about 5.5 and about 7.0, the method comprising addition of an alkali metal chloride salt at a concentration of between about 100 mM and about 200 mM, wherein the method stabilizes the coagulation protein for at least 3 months when stored at a refrigerated temperature, for example, at a temperature between about 2° C. and about 10° C.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile coagulation protein at a pH between about 5.5 and about 7.0, the method comprising addition of an alkali metal chloride salt at a concentration of between about 100 mM and about 200 mM, wherein the method stabilizes the coagulation protein for at least 6 months when stored at a refrigerated temperature, for example, at a temperature between about 2° C. and about 10° C.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile coagulation protein at a pH between about 5.5 and about 7.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 75 mM and about 200 mM, wherein the method stabilizes the coagulation protein for at least 6 months when stored at a refrigerated temperature, for example, at a temperature between about 2° C. and about 10° C.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile coagulation protein at a pH between about 5.5 and about 7.0, the method comprising addition of an alkali metal chloride salt at a concentration of between about 100 mM and about 200 mM, wherein the method stabilizes the coagulation protein for at least about one year when stored at a refrigerated temperature, for example, at a temperature between about 2° C. and about 10° C.
  • the present invention provides a method for stabilizing an aqueous formulation of a labile coagulation protein at a pH between about 5.5 and about 7.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 75 mM and about 200 mM, wherein the method stabilizes the coagulation protein for at least about one year when stored at a refrigerated temperature, for example, at a temperature between about 2° C. and about 10° C.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: between about 75 mM and about 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH between about 5:5 and about 7.5.
  • the present invention provides a storage stable, aqueous composition of a labile therapeutic protein comprising: between about 100 mM and about 200 mM of an alkali metal chloride salt; a stabilizing agent; and a pH between about 5.5 and about 7.0.
  • the labile therapeutic protein is a human or humanized protein.
  • the protein is a recombinant protein.
  • the protein is a plasma-derived protein.
  • the protein is an immunoglobulin.
  • the immunoglobulin is an IgG preparation.
  • the protein concentration of the IgG preparation is at least about 100 mg/mg.
  • the protein concentration of the IgG preparation is at least about 200 mg/mL.
  • the immunoglobulin is a recombinant antibody.
  • the composition is stable for at least 6 months when stored at between about 38° C. and about 42° C.
  • the composition is stable for at least 1 year when stored at between about 28° C. and about 32° C.
  • the pH of the composition is between about 5.5 and about 6.5.
  • the protein is a coagulation factor.
  • the coagulation factor is Factor VIII.
  • the pH of the composition is between about 6.0 and about 7.0.
  • the pH of the composition is 6.5 ⁇ 0.2.
  • the composition retains at least 80% of its Factor VIII activity when stored at a temperature between about 2° C. and about 8° C. for at least 3 months.
  • the coagulation factor is Factor VII.
  • the coagulation factor is Factor IX.
  • the coagulation factor is von Willebrand Factor (vWF).
  • the coagulation factor is a protein K-dependent coagulation complex.
  • the protein K-dependent coagulation complex comprises the coagulation factors Factor II, Factor IX, and Factor X.
  • the protein K-dependent coagulation complex further comprises Factor VII.
  • the labile protein is stable for less than 3 months in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the labile protein is stable for less than 2 months in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the labile protein is stable for less than 1 month in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the labile protein is stable for less than 2 weeks in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the concentration of the labile therapeutic protein is at least about 50 mg/mL.
  • the concentration of the labile therapeutic protein is at least about 100 mg/mL.
  • the concentration of the labile therapeutic protein is at least about 150 mg/mL.
  • the composition is formulated for subcutaneous or intramuscular administration.
  • the alkali metal chloride salt is sodium chloride.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine.
  • the concentration of the amino acid is at least about 100 mM.
  • the composition is stable for at least about 3 months.
  • the composition is stable for at least about 6 months.
  • the composition is stable for at least about 1 year.
  • the composition is stable for at least about 2 years.
  • the present invention provides a method for stabilizing a aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 7.5, the method comprising addition of an alkali metal chloride salt at a concentration of between about 75 mM and about 200 mM.
  • the present invention provides a method for stabilizing a aqueous formulation of a labile therapeutic protein at a pH between about 5.5 and about 7.0, the method comprising addition of an alkali metal chloride salt at a concentration of between about 100 mM and about 200 mM.
  • the solution further comprises a stabilizing agent.
  • the labile therapeutic protein is a human or humanized protein.
  • the protein is a recombinant protein.
  • the protein is a plasma-derived protein.
  • the protein is an immunoglobulin.
  • the immunoglobulin is an IgG preparation.
  • the protein concentration of the IgG preparation is at least about 150 mg/mg.
  • the protein concentration of the IgG preparation is at least about 200 mg/mg.
  • the immunoglobulin is a recombinant antibody.
  • the method stabilizes the immunoglobulin composition for at least 6 months when stored at between about 38° C. and about 42° C.
  • the method stabilizes the immunoglobulin composition for at least 1 year when stored at between about 28° C. and about 32° C.
  • the pH of the composition is between about 5.5 and about 6.5.
  • the protein is a coagulation protein.
  • the coagulation protein is Factor VIII.
  • the pH of the composition is between about 6.0 and about 7.0.
  • the pH of the composition is 6.5 ⁇ 0.2.
  • the method stabilizes the composition such that at least 80% of the Factor VIII activity is retained after storage at a temperature between about 2° C. and about 8° C. for at least 3 months.
  • the coagulation protein is Factor VII.
  • the coagulation protein is Factor IX.
  • the coagulation protein is von Willebrand Factor (vWF).
  • the coagulation protein is a protein K-dependent coagulation complex.
  • the protein K-dependent coagulation complex comprises the coagulation factors Factor II, Factor IX, and Factor X.
  • the protein K-dependent coagulation complex further comprises Factor VII.
  • the labile protein is stable for less than 3 months in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the labile protein is stable for less than 2 months in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the labile protein is stable for less than 1 month in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the labile protein is stable for less than 2 weeks in an aqueous formulation containing less than about 50 mM of an alkali metal chloride salt at a pH between about 5.5 and about 7.5.
  • the concentration of the labile therapeutic protein is at least about 50 mg/mL.
  • the concentration of the labile therapeutic protein is at least about 100 mg/mL.
  • the concentration of the labile therapeutic protein is at least about 150 mg/mL.
  • the composition is formulated for subcutaneous or intramuscular administration.
  • the alkali metal chloride salt is sodium chloride.
  • the stabilizing agent is an amino acid.
  • the amino acid is glycine.
  • the concentration of the amino acid is at least about 100 mM.
  • the method increases the time of stability for the composition by at least 25%.
  • the method increases the time of stability for the composition by at least 50%.
  • the method increases the time of stability for the composition by at least 100%.
  • the method increases the time of stability for the composition by at least 200%.
  • IgG compositions formulated at mildly acid to neutral pH were formulated at elevated temperatures (38° C. to 42° C.) to simulate longer time periods at room temperature (20° C. to 25° C.). Briefly, a 20% IgG composition, prepared as in Example 1, was divided into samples that were formulated with increasing salt concentrations (0 mM, 50 mM, 100 mM, and 150 mM) at mildly acid to neutral pHs (pH 5.5, 6.0, 6.5, 7.0, and 7.5). The aqueous formulations were then stored at between 38° C. and 42° C. for 6 months.
  • the stability of the immunoglobulin preparation is dependent upon both the pH and the salt concentration of the formulation.
  • Addition of 100 mM or 150 mM sodium chloride in the formulation provided additional stability, as compared to the protective effects seen for 50 mM sodium chloride in Example 1, at pHs between 6.0 and 7.5.
  • inclusion of 150 mM sodium chloride in of IgG compositions formulates at pHs between 6.0 and 7.5 reduced IgG aggregation by more than 50% on average.
  • Optimal stabilization was seen in formulations containing 150 mM sodium chloride at pH 6.5, in which aggregate formation was reduced more than 50% as compared to formulations with 50 mM sodium chloride and about 60% as compared to formulations with no sodium chloride. Consistent with previous observations, the addition of sodium chloride in IgG formulations at lower pH (5.5) results in a destabilizing effect.
  • Partobulin® NG Boxter Biosciences
  • Tetabulin® NG Tetabulin® NG
  • Partobulin® is a plasma-derived human anti-D antigen immunoglobulin preparation used for antenatal anti-D prophylaxis in Rh(D) negative pregnant women carrying Rh(D) positive fetuses, as well as for the treatment of Rh(D) negative persons after incompatible transfusions of Rh(D) positive blood or erythrocyte concentrate.
  • Tetabulin® is a plasma-derived human tetanus immunoglobulin used for post-tetanus exposure prophylaxis and therapy of clinically manifest tetanus. Both Partobulin® and Tetabulin® are typically formulated at between 100 g/L and 170 g/L human protein (of which at least 90% are immunoglobulin G) for intramuscular administration.
  • FIGS. 2 and 3 Aggregate formation over the course of 6 months for Tetabulin® NG and Partobulin® NG are shown in FIGS. 2 and 3 , respectively. Strikingly, no additional immunoglobulin aggregation occurred over the entire six months for either preparation formulated at pH 5.5 or 6.0 with 150 mM NaCl. Similarly, only slight aggregation was seen beginning at six months for both compositions at pH 6.5. In comparison, significant aggregation occurred within three months of storage at 28° C. to 32° C. for both Tetabulin® NG and Partobulin® NG formulated at pH 7.0 and 7.5.
  • both the Tetabulin® NG and Partobulin® NG formulations at pH 7.0 contained twice the starting amount of aggregates and both formulations at pH 7.5 contained about three times more immunoglobulin aggregates than at the start of the storage period.
  • the molecular size distributions of the IgG in the various formulations were determined by high performance size exclusion chromatography (HPLC-SEC) at the start of the storage period, after two weeks, 1 month, and 3 months of storage. The results of these characterizations are provided in Table 6.
  • anti-MIF titers were determined by ELISA for each formulation at the start of the storage period, and after 2 weeks, 1 month, and 3 months of storage at elevated temperatures (38° C. to 42° C.). As seen in FIG. 6 , despite low aggregation rates for the recombinant anti-MIF antibodies formulated at acid pH (pH 4.5), the Anti-MIF titer of this formulation dropped by 40% to 50% over the three month storage. Similarly, the Anti-MIF titer of the antibody preparation formulated at neutral pH (pH 7.3) was reduced by at least 20% over three months. However, the antibody preparations formulated at mildly acidic pH (pH 5.6 and 6.5) lost only about 10% of their starting Anti-MIF titer over the three month storage at elevated temperatures.
  • Factor VIII a coagulation factor
  • ADVATE recombinant FVIII
  • Samples of the FVIII preparation were then aliquoted and the pH adjusted to pH 5.5, 6.0, 6.5, 7.0, 7.5, or 8.0 with and without addition of 150 mM sodium chloride to give formulations with a starting Factor VIII activity in solution of 500 IU/mL.
  • the samples were stored at 2° C. to 8° C. for 12 weeks, during which time the residual FVIII activity was periodically monitored.
  • ADVATE ® Formulation 38 g/L mannitol 10 g/L trehalose 108 mEq/L sodium 12 mM histidine 12 mM Tris 1.9 mM calcium 0.15 g/L polysorbate-80 0.10 g/L glutathione
  • the effect sodium chloride has on the stability of an IgG composition formulated at acidic pH (4.4 to 4.9) was investigated. Briefly, an IgG composition was formulated with 0.25 M glycine, pH 4.4 to 4.9, at a final protein concentration of 10%. Sodium chloride was then added to aliquots of the formulation to a final concentration of 0 mM, 10 mM, 50 mM, or 100 mM. The molecular size distribution was then monitored by HPLC analysis after 1, 3, 6, 9, 12, 19, and 24 months of storage under refrigerated conditions (between 2° C. and 8° C.). The fixation of complement in the samples was also measured to determine the tolerability of the formulation. The results of the analysis are given in Table 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/235,307 2010-09-17 2011-09-16 STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph Abandoned US20120076779A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/235,307 US20120076779A1 (en) 2010-09-17 2011-09-16 STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38420910P 2010-09-17 2010-09-17
US13/235,307 US20120076779A1 (en) 2010-09-17 2011-09-16 STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph

Publications (1)

Publication Number Publication Date
US20120076779A1 true US20120076779A1 (en) 2012-03-29

Family

ID=44721088

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/235,307 Abandoned US20120076779A1 (en) 2010-09-17 2011-09-16 STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
US13/235,314 Active 2031-12-12 US8795658B2 (en) 2010-09-17 2011-09-16 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
US14/311,112 Active 2032-11-14 US9855331B2 (en) 2010-09-17 2014-06-20 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
US15/859,108 Abandoned US20180250401A1 (en) 2010-09-17 2017-12-29 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/235,314 Active 2031-12-12 US8795658B2 (en) 2010-09-17 2011-09-16 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
US14/311,112 Active 2032-11-14 US9855331B2 (en) 2010-09-17 2014-06-20 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
US15/859,108 Abandoned US20180250401A1 (en) 2010-09-17 2017-12-29 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph

Country Status (23)

Country Link
US (4) US20120076779A1 (ja)
EP (3) EP2616090B8 (ja)
JP (4) JP2013544762A (ja)
KR (1) KR101879885B1 (ja)
CN (2) CN103282042B (ja)
AR (3) AR083035A1 (ja)
AU (2) AU2011301803A1 (ja)
BR (1) BR112013006308B1 (ja)
CA (2) CA2810734A1 (ja)
CL (1) CL2013000724A1 (ja)
CO (1) CO6660498A2 (ja)
DK (1) DK2616090T3 (ja)
EA (2) EA027353B1 (ja)
ES (1) ES2959479T3 (ja)
FI (1) FI2616090T3 (ja)
IL (1) IL225093B (ja)
MX (1) MX351706B (ja)
MY (1) MY188828A (ja)
PL (1) PL2616090T3 (ja)
PT (1) PT2616090T (ja)
SG (1) SG188487A1 (ja)
TW (2) TW201213342A (ja)
WO (2) WO2012037534A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110066111A1 (en) * 2009-09-17 2011-03-17 Wolfgang Teschner Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US10301376B2 (en) 2008-03-17 2019-05-28 Baxalta GmbH Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
WO2022064448A1 (en) * 2020-09-27 2022-03-31 Emergent Biosolutions Canada Inc. Hyperimmune globulin formulations

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
EA027353B1 (ru) 2010-09-17 2017-07-31 Баксалта Инкорпорейтид СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
PL2994160T3 (pl) * 2013-05-06 2019-10-31 Baxalta Inc Leczenie subpopulacji osób z chorobą alzheimera z użyciem połączonej immunoglobuliny g
KR102192494B1 (ko) 2014-08-04 2020-12-18 시에스엘 리미티드 인자 viii 제형
KR20170096178A (ko) * 2014-12-19 2017-08-23 프로메틱 바이오 테라퓨틱스 인코포레이티드 플라스미노겐을 포함하는 약학 조성물 및 이의 용도
CN104826117B (zh) * 2015-05-05 2017-11-14 广东卫伦生物制药有限公司 用于人体血清免疫球蛋白溶液制剂的储存稳定剂
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CN109496149B (zh) * 2016-01-13 2022-10-14 根马布股份公司 抗体及其药物缀合物的制剂
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
TW201827052A (zh) * 2016-10-26 2018-08-01 日商安斯泰來製藥股份有限公司 安定的醫藥組成物
WO2018181876A1 (ja) * 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
WO2019199476A1 (en) * 2018-04-12 2019-10-17 Amgen Inc. Methods for making stable protein compositions
CN114072420A (zh) 2019-07-04 2022-02-18 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586573B1 (en) * 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3310150A1 (de) 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
DE3422000A1 (de) 1984-06-14 1985-12-19 Albert Schrem Werkzeugfabrik GmbH, 7928 Giengen Druckmittelbetaetigte spannvorrichtung zum spannen von werkzeugen oder werkstuecken
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3684546D1 (de) 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US4786726A (en) 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
FR2638643B1 (fr) 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
AU4803890A (en) * 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
ES2129076T5 (es) * 1993-12-27 2003-05-16 Zlb Bioplasma Ag Procedimiento para la preparacion de un concentrado de inmunoglobulina g anti-d y composicion farmaceutica que lo contiene.
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4460762B2 (ja) 1997-10-15 2010-05-12 旭化成ファーマ株式会社 トロンボモジュリン水溶液注射剤の貯蔵・流通時の品質保持方法
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
JP2002501901A (ja) 1998-01-30 2002-01-22 ライノファーマ エイエス 草木の抗ウイルス剤
DE59914490D1 (de) 1998-11-10 2007-10-18 Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
CN101066997B (zh) 1999-03-25 2013-03-27 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
ES2477996T3 (es) * 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
US6555391B1 (en) 2000-08-15 2003-04-29 Baxter International, Inc. Methods of conditioning an affinity resin after storage
CA2447791A1 (en) 2001-06-13 2002-12-19 Neslihan Delacruz Methods of culturing animal cells and polypeptide production in animal cells
US20060024346A1 (en) * 2004-07-29 2006-02-02 Brody Richard S Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
DK1475101T3 (da) 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
US20060182740A1 (en) 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7857828B2 (en) 2003-01-30 2010-12-28 Integrated Vascular Systems, Inc. Clip applier and methods of use
EP1592440A4 (en) * 2003-02-10 2007-07-11 Elan Pharm Inc IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME
CN102258464A (zh) 2003-04-04 2011-11-30 健泰科生物技术公司 高浓度抗体和蛋白制剂
CN1816356A (zh) * 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
KR20120089307A (ko) 2004-02-12 2012-08-09 메르크 파텐트 게엠베하 항－ｅｇｆｒ 항체들의 고농축 액체 제형물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PT1841863E (pt) 2005-01-14 2010-10-25 Bayer Healthcare Llc Método para a purificação de factor vii
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2615122A1 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
KR100667860B1 (ko) 2005-10-18 2007-01-11 주식회사 녹십자 고순도 사람 혈액응고 제9인자의 정제 방법
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
WO2007077217A2 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
MX2009003982A (es) * 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
CN101199845B (zh) * 2006-12-14 2012-05-23 上海国健生物技术研究院 一种稳定的抗IgE人源化单抗制剂
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
DK2125866T3 (da) 2007-02-28 2013-07-29 Baxter Int Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
US7598560B2 (en) 2007-03-30 2009-10-06 Kavalieros Jack T Hetero-bimos injection process for non-volatile flash memory
EP2077859A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODY FORMULATION
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
US20100120093A1 (en) 2008-11-12 2010-05-13 Baxter International Inc. Method of Producing Serum-Free Insulin-Free Factor VII
WO2010062896A1 (en) 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8318161B2 (en) 2009-03-06 2012-11-27 Genentech, Inc. Anti-oxidized LDL antibody formulation
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US8821879B2 (en) * 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US20110256135A1 (en) 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
EA027353B1 (ru) 2010-09-17 2017-07-31 Баксалта Инкорпорейтид СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586573B1 (en) * 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10301376B2 (en) 2008-03-17 2019-05-28 Baxalta GmbH Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
USRE49967E1 (en) 2008-03-17 2024-05-14 Takeda Pharmaceutical Company Limited Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
US20110066111A1 (en) * 2009-09-17 2011-03-17 Wolfgang Teschner Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
WO2022064448A1 (en) * 2020-09-27 2022-03-31 Emergent Biosolutions Canada Inc. Hyperimmune globulin formulations

Also Published As

Publication number Publication date
EP2616090A1 (en) 2013-07-24
CA2810731A1 (en) 2012-03-22
EP2616090B8 (en) 2023-10-04
IL225093B (en) 2018-05-31
SG188487A1 (en) 2013-05-31
JP2018203784A (ja) 2018-12-27
AU2011301807C1 (en) 2016-02-11
WO2012037534A1 (en) 2012-03-22
AU2011301807A1 (en) 2013-03-28
TW201217395A (en) 2012-05-01
MX351706B (es) 2017-10-25
WO2012037530A1 (en) 2012-03-22
DK2616090T3 (da) 2023-09-18
US20120076772A1 (en) 2012-03-29
CL2013000724A1 (es) 2014-03-21
KR101879885B1 (ko) 2018-07-18
US20140370000A1 (en) 2014-12-18
PL2616090T3 (pl) 2023-12-18
CN103282042A (zh) 2013-09-04
JP2013544763A (ja) 2013-12-19
JP2017071631A (ja) 2017-04-13
CN104524566A (zh) 2015-04-22
US9855331B2 (en) 2018-01-02
MY188828A (en) 2022-01-06
CA2810734A1 (en) 2012-03-22
EA201692397A1 (ru) 2017-08-31
AR122552A2 (es) 2022-09-21
AU2011301807B2 (en) 2015-07-30
EP2616091A1 (en) 2013-07-24
EP4289445A2 (en) 2023-12-13
EP4289445A3 (en) 2024-02-21
AR083035A1 (es) 2013-01-30
PT2616090T (pt) 2023-10-16
MX2013003018A (es) 2013-06-28
FI2616090T3 (fi) 2023-09-21
BR112013006308B1 (pt) 2022-03-22
AU2011301803A1 (en) 2013-03-21
JP2013544762A (ja) 2013-12-19
AR083034A1 (es) 2013-01-30
CN103282042B (zh) 2014-12-10
JP6055412B2 (ja) 2016-12-27
EP2616090B1 (en) 2023-08-23
EA201390400A1 (ru) 2013-08-30
ES2959479T3 (es) 2024-02-26
US8795658B2 (en) 2014-08-05
EA032336B1 (ru) 2019-05-31
KR20130099956A (ko) 2013-09-06
TW201213342A (en) 2012-04-01
US20180250401A1 (en) 2018-09-06
CO6660498A2 (es) 2013-04-30
CN104524566B (zh) 2018-08-07
BR112013006308A2 (pt) 2016-06-07
EA027353B1 (ru) 2017-07-31
TWI621625B (zh) 2018-04-21

Similar Documents

Publication Publication Date Title
US20120076779A1 (en) STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
US7390786B2 (en) Protein formulations with reduced viscosity and uses thereof
US8298530B2 (en) Stable lyophilized pharmaceutical formulation of IgG antibodies
CN111375057A (zh) 一种包含抗Her2单克隆抗体的药物配制剂
AU2015249186B2 (en) Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutal ph

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUTTERWECK, HARALD ARNO;BAUER, THERESA FRIEDERIKE;HOFBAUER, LUCIA;AND OTHERS;SIGNING DATES FROM 20111021 TO 20111028;REEL/FRAME:027363/0001

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUTTERWECK, HARALD ARNO;BAUER, THERESA FRIEDERIKE;HOFBAUER, LUCIA;AND OTHERS;SIGNING DATES FROM 20111021 TO 20111028;REEL/FRAME:027363/0001

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION